[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Global Cooling Inc\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":300},{"warningLetters":4,"total":299},[5,31,53,73,97,120,139,158,175,194,211,229,247,265,282],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},1476,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2024-05-07T13:20:00Z\">05\u002F07\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-04-30T04:00:00Z\">04\u002F30\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fglobal-cosmetics-company-limited-677948-04302024\">Global Cosmetics Company Limited\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ms. Ranki Liu\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Product Technical Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Global Cosmetics Company Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>No. 13 Gaobao Road, Changping Town\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Dongguan Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Guangdong Sheng\u003C\u002Fspan>, \u003Cspan>523581\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-24-35\u003C\u002Fp>\n\n\u003Cp>April 30, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Liu:\u003C\u002Fp>\n\n\u003Cp>Your facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our September 12, 2022 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility, Global Cosmetics (China) Company Limited, FEI 3013749236, at No. 13 Gaobao Road, Changping Town, Dongguan, Guangdong 523581, China.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\n\n\u003Cp>Following review of records and other information provided pursuant to section 704(a)(4) of the FD&amp;C Act, significant violations were observed including, but not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You manufactured OTC drug products including hand sanitizer.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Based on the records and information you provided, you did not demonstrate that you are adequately testing the identity of incoming components used in the manufacture of your drug products. You also did not demonstrate that you are adequately testing your active ingredient ethanol for methanol.\u003C\u002Fp>\n\n\u003Cp>Without adequate testing you do not have scientific evidence that your raw materials conform to appropriate specifications prior to use in the manufacture of your drug products. As a manufacturer, you have a responsibility to sample, test, and examine drug components before use in production to assure adequate quality, including testing for the presence of methanol in ethanol.\u003C\u002Fp>\n\n\u003Cp>The use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document, \u003Cem>Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol\u003C\u002Fem>, at: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The records and information you provided did not demonstrate that your firm has an adequate stability program for the OTC hand sanitizer drug products that you manufacture. For example, your firm provided a stability test report which only included 12 weeks of stability data for a batch of hand sanitizer. In addition, you did not provide data demonstrating that adequate chemical and microbiological testing is performed on your drug products during stability testing.\u003C\u002Fp>\n\n\u003Cp>Without appropriate stability studies, you do not have scientific evidence to support whether your drug products meet established specifications and retain their quality attributes through their labeled expiry.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The records and information you provided demonstrate that your quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. Your QU is responsible for fully exercising its authority and responsibilities. FDA is concerned that your QU may not be conducting appropriate oversight regarding CGMP operations.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>If your firm intends to resume manufacturing drugs for the U.S. market, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements before resuming drug manufacturing operations. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of all corrective action and preventive action (CAPA) before you pursue resolution of your firm’s compliance status per FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on February 16, 2024.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Global Cosmetics (China) Company Limited, No. 13 Gaobao Road, Changping Town, Dongguan, Guangdong 523581, China, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3013749236 and ATTN: Joel Hustedt.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\n\u003Cbr>\nCC:\u003C\u002Fp>\n\n\u003Cp>Registered US Agent\u003Cbr>\nLiberty Management Group Ltd.\u003Cbr>\n75 Executive Drive, Suite 114\u003Cbr>\nAurora, IL 60504\u003Cbr>\nmanoj@libertymanagement.us\u003C\u002Fp>\n\n\u003Cp>_____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, the FDA published the Guidance for Industry: \u003Cem>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fem> on March 19, 2020, and subsequently updated the guidance several times. This guidance communicated the Agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepared alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance&nbsp;were present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. The guidance was withdrawn effective December 31, 2021 (86 Fed Reg at 56960). Because Global Cosmetics (China) Company Limited’s hand sanitizer products were not prepared under the circumstances described in this guidance, they do not fall within any temporary agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&amp;C Act.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMs. Ranki Liu\n\nRecipient Title\n\nProduct Technical Manager\n\nGlobal Cosmetics Company Limited\n\nNo. 13 Gaobao Road, Changping Town\n\nDongguan Shi\n\nGuangdong Sheng, 523581\n\nChina\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-24-35\n\nApril 30, 2024\n\nDear Ms. Liu:\n\nYour facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our September 12, 2022 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, Global Cosmetics (China) Company Limited, FEI 3013749236, at No. 13 Gaobao Road, Changping Town, Dongguan, Guangdong 523581, China.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 351(a)(2)(B)).\n\nFollowing review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant violations were observed including, but not limited to, the following:\n\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1).\n\nYou manufactured OTC drug products including hand sanitizer.1 Based on the records and information you provided, you did not demonstrate that you are adequately testing the identity of incoming components used in the manufacture of your drug products. You also did not demonstrate that you are adequately testing your active ingredient ethanol for methanol.\n\nWithout adequate testing you do not have scientific evidence that your raw materials conform to appropriate specifications prior to use in the manufacture of your drug products. As a manufacturer, you have a responsibility to sample, test, and examine drug components before use in production to assure adequate quality, including testing for the presence of methanol in ethanol.\n\nThe use of ethanol contaminated with methanol has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document, Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol, at: https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F173005\u002Fdownload.\n\n2. Your firm failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a)).\n\nThe records and information you provided did not demonstrate that your firm has an adequate stability program for the OTC hand sanitizer drug products that you manufacture. For example, your firm provided a stability test report which only included 12 weeks of stability data for a batch of hand sanitizer. In addition, you did not provide data demonstrating that adequate chemical and microbiological testing is performed on your drug products during stability testing.\n\nWithout appropriate stability studies, you do not have scientific evidence to support whether your drug products meet established specifications and retain their quality attributes through their labeled expiry.\n\n3. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\n\nThe records and information you provided demonstrate that your quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. Your QU is responsible for fully exercising its authority and responsibilities. FDA is concerned that your QU may not be conducting appropriate oversight regarding CGMP operations.\n\nSee FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nCGMP Consultant Recommended\n\nIf your firm intends to resume manufacturing drugs for the U.S. market, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements before resuming drug manufacturing operations. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of all corrective action and preventive action (CAPA) before you pursue resolution of your firm’s compliance status per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nFDA placed your firm on Import Alert 66-40 on February 16, 2024.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Global Cosmetics (China) Company Limited, No. 13 Gaobao Road, Changping Town, Dongguan, Guangdong 523581, China, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3013749236 and ATTN: Joel Hustedt.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nCC:\n\nRegistered US Agent\n\nLiberty Management Group Ltd.\n\n75 Executive Drive, Suite 114\n\nAurora, IL 60504\n\nmanoj@libertymanagement.us\n\n_____________________\n\n1 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, the FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times. This guidance communicated the Agency’s temporary policy that we did not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepared alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance were present. These circumstances included preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. The guidance was withdrawn effective December 31, 2021 (86 Fed Reg at 56960). Because Global Cosmetics (China) Company Limited’s hand sanitizer products were not prepared under the circumstances described in this guidance, they do not fall within any temporary agency policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&C Act.","Global Cosmetics Company Limited","global-cosmetics-company-limited-677948-04302024","2026-08-18T06:42:28.856152+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fglobal-cosmetics-company-limited-677948-04302024","2026-10-26T08:08:46.38655+00:00","Warning Letter","Issued","2024-05-07","677948","Drugs","Ms. Ranki Liu","2026-08-20T00:07:04.566+00:00","VIA UPS","2024-04-30",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":49,"body_fetched_at":50,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":52,"medical_device_id":19,"response_letter_date":19},2403,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2022-10-11T13:20:00Z\">10\u002F11\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-08-01T04:00:00Z\">08\u002F01\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdf-global-inc-633242-08012022\">DF Global, Inc.\u003C\u002Fa>","Division of West Coast Imports","Foreign Supplier Verification Program (FSVP)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Sang Ki Lee\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Branch President &amp; CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>DF Global, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6221 Randolph St\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Commerce\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>90040-3514\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:SK.LEE@DAMTUH.COM\"> SK.LEE@DAMTUH.COM\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of West Coast Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>August 1, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Re: CMS # 633242\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Sang Ki Lee:\u003C\u002Fp>\n\n\u003Cp>On March 30, 2022, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of DF Global, Inc., located at 6221 Randolph St, Commerce, CA 90040-3514. We also conducted an inspection on January 15, 2020. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\u003C\u002Fp>\n\n\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the following foods you import: Honey Hallabong Tea, \u003Cstrong>(b)(4)\u003C\u002Fstrong> Ginger Lemon Tea, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Tea imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the FSVP inspection, our investigator provided you with a Form FDA 483a, FSVP Observations.\u003C\u002Fp>\n\n\u003Cp>We acknowledge receipt of your response dated April 12, 2022, which stated that you have had an FSVP for all of your imported foods since February 2020 but you did not know which documents to provide during the most recent inspection. Your response also included records associated with your FSVPs for Honey Hallabong Tea, \u003Cstrong>(b)(4)\u003C\u002Fstrong> Ginger Lemon Tea, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Tea imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, such as copies of procedures, a certificate of HACCP Applied Establishment for \u003Cstrong>(b)(4)\u003C\u002Fstrong> from the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, an audit report for \u003Cstrong>(b)(4)\u003C\u002Fstrong> from the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and hazard analyses for Honey Hallabong Tea, \u003Cstrong>(b)(4)\u003C\u002Fstrong> Ginger Lemon Tea, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Tea imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We address your response below.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>1. You did not conduct a hazard analysis for each type of food you import to determine whether there are any hazards requiring a control, as required by 21 CFR 1.504. A hazard means any biological, chemical (including radiological), or physical agent that is reasonably likely to cause illness or injury (see 21 CFR 1.500). A hazard requiring a control means a known or reasonably foreseeable hazard for which a person knowledgeable about the safe manufacturing, processing, packing, or holding of food would, based on the outcome of a hazard analysis (which includes an assessment of the probability that the hazard will occur in the absence of controls or measures and the severity of the illness or injury if the hazard were to occur), establish one or more controls or measures to significantly minimize or prevent the hazard in a food and components to manage those controls or measures (such as monitoring, corrections or corrective actions, verification, and records) as appropriate to the food, the facility, and the nature of the control or measure and its role in the facility’s food safety system (see 21 CFR 1.500). Specifically, in your hazard analysis for “Tea (powder type: \u003Cstrong>(b)(4)\u003C\u002Fstrong>, etc),” which we understand to be for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Tea imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you did not identify the chemical hazards of undeclared allergens or natural toxins, such as mycotoxins in peanuts and tree nuts (which includes walnuts and almonds). According to the product labels you provided during the most recent inspection, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which are food allergens. Food allergens are reasonably likely to cause illness or injury when undeclared on the package label, such that a control is required to ensure proper labeling. Moreover, you should evaluate whether food allergen controls are required to prevent or significantly minimize allergen cross-contact in the Honey Hallabong Tea and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Ginger Lemon Tea products manufactured by the same foreign supplier. You should also evaluate whether mycotoxins in peanuts and tree nuts are a hazard requiring a control for \u003Cstrong>(b)(4)\u003C\u002Fstrong> Tea. However, you did not provide any information that suggests that food allergens or mycotoxins were identified as hazards requiring a control.\u003C\u002Fp>\n\n\u003Cp>2. You did not meet the requirements to perform foreign supplier verification activities in accordance with 21 CFR 1.506(e) for the products you import. For an onsite audit, you must retain documentation of each onsite audit, including the audit procedures, the dates the audit was conducted, the conclusions of the audit, any corrective actions taken in response to significant deficiencies identified during the audit, and documentation that the audit was conducted by a qualified auditor (21 CFR 1.506(e)(1)(i)(D)). For a food that is subject to one or more FDA food safety regulations, an onsite audit of the foreign supplier must consider such regulations and include a review of the supplier’s written food safety plan, if any, and its implementation, for the hazard being controlled (21 CFR 1.506(e)(1)(i)(B)). Your third-party onsite audit report of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, from the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, dated April 22 through 23, 2021, includes the audit procedures, the dates the audit was conducted, and the conclusions of the audit. The audit report notes multiple deficiencies by the foreign supplier, including failure to establish standards for cleaning and disinfection, insufficient periodic inspection and calibration of refrigerators and measuring instruments, insufficient identification of possible hazards, insufficient preventive measures of raw materials and hazardous factors, and lack of understanding of concepts and procedures for hazard analysis. However, the audit report does not describe, nor have you provided other documentation of, the corrective actions taken in response to these significant deficiencies. You also did not provide any documentation showing that the audit assessed compliance with FDA food safety regulations, reviewed the supplier’s written food safety plan, or was conducted by a qualified auditor.\u003C\u002Fp>\n\n\u003Cp>Additionally, as indicated above, the third-party onsite audit report found several issues with your foreign supplier’s performance. Note that when you become aware of new information about factors related to a foreign supplier’s performance and the risk posed by a food (see 21 CFR 1.505(a)(1) for a list of factors), such as the foreign supplier’s procedures, processes, and practices related to the safety of the food, applicable FDA food safety regulations and information relevant to the foreign supplier’s compliance with those regulations, or the foreign supplier’s food safety history, you must promptly reevaluate the concerns associated with these factors and document your reevaluation (see 21 CFR 1.505(c)).\u003C\u002Fp>\n\n\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(3)(A)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>As a responsible official of a facility that manufactures\u002Fprocesses, packs, or holds food for human or animal consumption in the United States, you are responsible for ensuring that your overall operation and the products you distribute are in compliance with the law.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(3)(A)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States from the identified foreign supplier on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>We also offer the following comment:\u003C\u002Fp>\n\n\u003Cp>During the most recent close out inspection, you stated that your Sales Manager and other personnel in your firm have received FSVP training. In addition, in your response to the Form 483a, you included several records prepared by your consultant, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, you did not provide FDA with training records or certificates of FSVP course completion for the personnel in your firm or \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Note that a qualified individual must develop your FSVP and perform FSVP activities, and a qualified individual must have the education, training, or experience (or a combination thereof) necessary to perform their assigned activities, as required by 21 CFR 1.503(a). This includes any consultants you may have relied on to develop your FSVP or perform FSVP activities.\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes, such as a copy of your revised FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Sandra K. Wangen Compliance Officer, Division of West Coast Imports, 949 Market St, Suite 602, Tacoma, WA 98402. If you have any questions regarding this letter, you may contact Sandra K. Wangen via email at sandra.wangen@fda.hhs.gov. Please reference CMS # 633242 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Dr. Kathleen Turner\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of West Coast Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nSang Ki Lee\n\nRecipient Title\n\nBranch President & CEO\n\nDF Global, Inc.\n\n6221 Randolph St\n\nCommerce, CA 90040-3514\n\nUnited States\n\nSK.LEE@DAMTUH.COM\n\nIssuing Office:\n\nDivision of West Coast Imports\n\nUnited States\n\nAugust 1, 2022\n\nWARNING LETTER\n\nRe: CMS # 633242\n\nDear Mr. Sang Ki Lee:\n\nOn March 30, 2022, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of DF Global, Inc., located at 6221 Randolph St, Commerce, CA 90040-3514. We also conducted an inspection on January 15, 2020. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the following foods you import: Honey Hallabong Tea, (b)(4) Ginger Lemon Tea, and (b)(4) Tea imported from (b)(4) located in (b)(4). Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of the FSVP inspection, our investigator provided you with a Form FDA 483a, FSVP Observations.\n\nWe acknowledge receipt of your response dated April 12, 2022, which stated that you have had an FSVP for all of your imported foods since February 2020 but you did not know which documents to provide during the most recent inspection. Your response also included records associated with your FSVPs for Honey Hallabong Tea, (b)(4) Ginger Lemon Tea, and (b)(4) Tea imported from (b)(4) located in (b)(4), such as copies of procedures, a certificate of HACCP Applied Establishment for (b)(4) from the (b)(4), an audit report for (b)(4) from the (b)(4), and hazard analyses for Honey Hallabong Tea, (b)(4) Ginger Lemon Tea, and (b)(4) Tea imported from (b)(4). We address your response below.\n\nYour significant violations of the FSVP regulation are as follows:\n\n1. You did not conduct a hazard analysis for each type of food you import to determine whether there are any hazards requiring a control, as required by 21 CFR 1.504. A hazard means any biological, chemical (including radiological), or physical agent that is reasonably likely to cause illness or injury (see 21 CFR 1.500). A hazard requiring a control means a known or reasonably foreseeable hazard for which a person knowledgeable about the safe manufacturing, processing, packing, or holding of food would, based on the outcome of a hazard analysis (which includes an assessment of the probability that the hazard will occur in the absence of controls or measures and the severity of the illness or injury if the hazard were to occur), establish one or more controls or measures to significantly minimize or prevent the hazard in a food and components to manage those controls or measures (such as monitoring, corrections or corrective actions, verification, and records) as appropriate to the food, the facility, and the nature of the control or measure and its role in the facility’s food safety system (see 21 CFR 1.500). Specifically, in your hazard analysis for “Tea (powder type: (b)(4), etc),” which we understand to be for your (b)(4) Tea imported from (b)(4), located in (b)(4), you did not identify the chemical hazards of undeclared allergens or natural toxins, such as mycotoxins in peanuts and tree nuts (which includes walnuts and almonds). According to the product labels you provided during the most recent inspection, (b)(4), which are food allergens. Food allergens are reasonably likely to cause illness or injury when undeclared on the package label, such that a control is required to ensure proper labeling. Moreover, you should evaluate whether food allergen controls are required to prevent or significantly minimize allergen cross-contact in the Honey Hallabong Tea and (b)(4) Ginger Lemon Tea products manufactured by the same foreign supplier. You should also evaluate whether mycotoxins in peanuts and tree nuts are a hazard requiring a control for (b)(4) Tea. However, you did not provide any information that suggests that food allergens or mycotoxins were identified as hazards requiring a control.\n\n2. You did not meet the requirements to perform foreign supplier verification activities in accordance with 21 CFR 1.506(e) for the products you import. For an onsite audit, you must retain documentation of each onsite audit, including the audit procedures, the dates the audit was conducted, the conclusions of the audit, any corrective actions taken in response to significant deficiencies identified during the audit, and documentation that the audit was conducted by a qualified auditor (21 CFR 1.506(e)(1)(i)(D)). For a food that is subject to one or more FDA food safety regulations, an onsite audit of the foreign supplier must consider such regulations and include a review of the supplier’s written food safety plan, if any, and its implementation, for the hazard being controlled (21 CFR 1.506(e)(1)(i)(B)). Your third-party onsite audit report of (b)(4), from the (b)(4), dated April 22 through 23, 2021, includes the audit procedures, the dates the audit was conducted, and the conclusions of the audit. The audit report notes multiple deficiencies by the foreign supplier, including failure to establish standards for cleaning and disinfection, insufficient periodic inspection and calibration of refrigerators and measuring instruments, insufficient identification of possible hazards, insufficient preventive measures of raw materials and hazardous factors, and lack of understanding of concepts and procedures for hazard analysis. However, the audit report does not describe, nor have you provided other documentation of, the corrective actions taken in response to these significant deficiencies. You also did not provide any documentation showing that the audit assessed compliance with FDA food safety regulations, reviewed the supplier’s written food safety plan, or was conducted by a qualified auditor.\n\nAdditionally, as indicated above, the third-party onsite audit report found several issues with your foreign supplier’s performance. Note that when you become aware of new information about factors related to a foreign supplier’s performance and the risk posed by a food (see 21 CFR 1.505(a)(1) for a list of factors), such as the foreign supplier’s procedures, processes, and practices related to the safety of the food, applicable FDA food safety regulations and information relevant to the foreign supplier’s compliance with those regulations, or the foreign supplier’s food safety history, you must promptly reevaluate the concerns associated with these factors and document your reevaluation (see 21 CFR 1.505(c)).\n\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\n\n(b)(3)(A)\n\nAs a responsible official of a facility that manufactures\u002Fprocesses, packs, or holds food for human or animal consumption in the United States, you are responsible for ensuring that your overall operation and the products you distribute are in compliance with the law.\n\n(b)(3)(A)\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States from the identified foreign supplier on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act.\n\nWe also offer the following comment:\n\nDuring the most recent close out inspection, you stated that your Sales Manager and other personnel in your firm have received FSVP training. In addition, in your response to the Form 483a, you included several records prepared by your consultant, (b)(4). However, you did not provide FDA with training records or certificates of FSVP course completion for the personnel in your firm or (b)(4). Note that a qualified individual must develop your FSVP and perform FSVP activities, and a qualified individual must have the education, training, or experience (or a combination thereof) necessary to perform their assigned activities, as required by 21 CFR 1.503(a). This includes any consultants you may have relied on to develop your FSVP or perform FSVP activities.\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes, such as a copy of your revised FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: Sandra K. Wangen Compliance Officer, Division of West Coast Imports, 949 Market St, Suite 602, Tacoma, WA 98402. If you have any questions regarding this letter, you may contact Sandra K. Wangen via email at sandra.wangen@fda.hhs.gov. Please reference CMS # 633242 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nDr. Kathleen Turner\n\nProgram Division Director\n\nDivision of West Coast Imports","DF Global, Inc.","df-global-inc-633242-08012022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdf-global-inc-633242-08012022","2026-10-26T08:08:23.988115+00:00","2022-10-11","633242","Food & Beverages","Sang Ki Lee","2026-08-20T01:30:51.828+00:00","Via Express Delivery","2022-08-01",{"id":54,"raw":55,"subject":38,"body_html":60,"body_text":61,"firm_name":62,"letter_id":63,"created_at":64,"fei_number":19,"letter_url":65,"updated_at":66,"action_type":22,"case_status":23,"posted_date":67,"marcs_cms_no":68,"product_type":48,"closeout_date":19,"issuing_office":69,"recipient_name":70,"body_fetched_at":71,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":72,"medical_device_id":19,"response_letter_date":19},1644,[56,57,58,59,38,13,13,13],"\u003Ctime datetime=\"2024-01-30T14:20:00Z\">01\u002F30\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-12-01T05:00:00Z\">12\u002F01\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fjjr-global-inc-665855-12012023\">JJR Global Inc.\u003C\u002Fa>"," Division of Southwest Imports","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Paul S Joseph\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>JJR Global Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4015 Mission Valley Dr\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Missouri City\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>77459-3751\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Southwest Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>December 01, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Re: CMS #665855\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Paul S Joseph:\u003C\u002Fp>\n\n\u003Cp>On August 9 to August 10, 2023, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of JJR Global Inc., located at 808 Summer Park Dr, Suite 200, Stafford, TX 77477-5569. We also conducted inspections on February 11 to March 04, 2021 and August 07, 2018. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\u003C\u002Fp>\n\n\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We acknowledge receipt of your response dated August 15, 2023. In your response, you stated you have visited each of your foreign suppliers and will work to develop your firm’s FSVPs. You did not provide any documentation of the activities that you are taking in order to comply. We are unable to evaluate the adequacy of your response because you did not provide documentation demonstrating evidence of the specific steps you have taken to comply with FSVP for the food products you import.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including the following foods:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong>, Sweet Mango Chutney, and Coriander Chutney (Frozen) from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>During the inspection you provided a food safety plan you obtained from your foreign supplier. Although these documents could be relevant to development of an FSVP, you did not provide a record of your review of the relevant documents or explain how they would apply to your FSVP program. Thus, these documents do not constitute an FSVP, as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a).\u003C\u002Fp>\n\n\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>In addition, FDA has determined \u003Cstrong>(b)(3)(A)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import from the identified foreign suppliers on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert #99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP, and any additional information that you wish to supply relevant to your compliance with the FSVP regulation). If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Zumera Ajani, Compliance Officer, Division of Southwest Imports, at Zumera.Ajani@fda.hhs.gov. If you have any questions regarding this letter, you may contact CO Ajani via email. Please reference CMS #665855 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Todd Cato\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of Southwest Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nPaul S Joseph\n\nRecipient Title\n\nPresident\n\nJJR Global Inc.\n\n4015 Mission Valley Dr\n\nMissouri City, TX 77459-3751\n\nUnited States\n\nIssuing Office:\n\nDivision of Southwest Imports\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nDecember 01, 2023\n\nWARNING LETTER\n\nRe: CMS #665855\n\nDear Mr. Paul S Joseph:\n\nOn August 9 to August 10, 2023, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of JJR Global Inc., located at 808 Summer Park Dr, Suite 200, Stafford, TX 77477-5569. We also conducted inspections on February 11 to March 04, 2021 and August 07, 2018. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We acknowledge receipt of your response dated August 15, 2023. In your response, you stated you have visited each of your foreign suppliers and will work to develop your firm’s FSVPs. You did not provide any documentation of the activities that you are taking in order to comply. We are unable to evaluate the adequacy of your response because you did not provide documentation demonstrating evidence of the specific steps you have taken to comply with FSVP for the food products you import.\n\nYour significant violations of the FSVP regulation are as follows:\n\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including the following foods:\n\n(b)(4), Sweet Mango Chutney, and Coriander Chutney (Frozen) from (b)(4) located in (b)(4)\n\nDuring the inspection you provided a food safety plan you obtained from your foreign supplier. Although these documents could be relevant to development of an FSVP, you did not provide a record of your review of the relevant documents or explain how they would apply to your FSVP program. Thus, these documents do not constitute an FSVP, as required by section 805 of the FD&C Act and 21 CFR 1.502(a).\n\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1 subpart L.\n\nIn addition, FDA has determined (b)(3)(A)\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import from the identified foreign suppliers on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert #99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP, and any additional information that you wish to supply relevant to your compliance with the FSVP regulation). If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: Zumera Ajani, Compliance Officer, Division of Southwest Imports, at Zumera.Ajani@fda.hhs.gov. If you have any questions regarding this letter, you may contact CO Ajani via email. Please reference CMS #665855 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nTodd Cato\n\nProgram Division Director\n\nDivision of Southwest Imports","JJR Global Inc.","jjr-global-inc-665855-12012023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fjjr-global-inc-665855-12012023","2026-10-26T08:09:04.378486+00:00","2024-01-30","665855","Division of Southwest Imports","Paul S Joseph","2026-08-20T00:21:10.519+00:00","2023-12-01",{"id":74,"raw":75,"subject":80,"body_html":82,"body_text":83,"firm_name":84,"letter_id":85,"created_at":18,"fei_number":19,"letter_url":86,"updated_at":87,"action_type":22,"case_status":88,"posted_date":89,"marcs_cms_no":90,"product_type":26,"closeout_date":91,"issuing_office":79,"recipient_name":92,"body_fetched_at":93,"delivery_method":94,"recipient_title":19,"reference_number":95,"action_taken_date":96,"medical_device_id":19,"response_letter_date":19},1075,[76,77,78,79,80,13,81,13],"\u003Ctime datetime=\"2025-02-04T05:00:00Z\">02\u002F04\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-01-16T05:00:00Z\">01\u002F16\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fglobal-calcium-pvt-limited-692000-01162025\">Global Calcium Pvt. Limited\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FActive Pharmaceutical Ingredient (API)\u002FAdulterated","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fglobal-calcium-house-1-692000-07302026\">\u003Ctime datetime=\"2026-07-30T04:00:00Z\">07\u002F30\u002F2026\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail - Delivery and Read Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-30\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Arif Vazirally\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Executive Chairman\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Global Calcium Pvt. Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>No. 882, 6th Cross, 6th Block\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Koramangala\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bengaluru\u003C\u002Fspan> \u003Cspan>560095\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-30\u003C\u002Fp>\u003Cp>January 16, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Vazirally:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Global Calcium Pvt. Limited, FEI 3004094136, at Bangalore - Hosur Highway, 125\u002F126, Sipcot Industrial Complex, Hosur, Tamil Nadu, India 635126, from July 29 to August 2, 2024.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for active pharmaceutical ingredients (APIs).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your APIs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your August 23, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific deviations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure of your quality unit to prepare, review, and approve documents related to the manufacturing of APIs in accordance with written procedures.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You provided production records for two different APIs that showed manufacturing activities occurred simultaneously on the same equipment. For example, your batch records and equipment logbooks show the same equipment including, but not limited to,\u003Cstrong>(b)(4)\u003C\u002Fstrong> were used at the same time to manufacture \u003Cstrong>(b)(4)\u003C\u002Fstrong> USP and \u003Cstrong>(b)(4)\u003C\u002Fstrong> USP.\u003C\u002Fp>\u003Cp>Additionally, you deleted multiple electronic records during the inspection. For example, on the initial morning of the inspection, investigators observed Microsoft Excel documents on a desktop computer in the Plant \u003Cstrong>(b)(4)\u003C\u002Fstrong> production office including, but not limited to, “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Cleaning validation samples,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Production Details-2024,” “Plant-\u003Cstrong>(b)(4)\u003C\u002Fstrong> production Report Jun-2024,” and “Planning June-2024.” On the second day, investigators returned to the production office to review these files. However, all files had been deleted and could not be recovered during the inspection. Without access to the files, the investigators were unable to determine their purpose and adequately evaluate your adherence to CGMP.\u003C\u002Fp>\u003Cp>In your response, you acknowledge your production head directed the creation of falsified manufacturing records to misrepresent API production activities so incentives could be claimed regarding production in plant \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Additionally, you state a lack of training and other factors resulted in deficient documentation control, then explain you have revised your SOP for document issuance and control. You also state Microsoft Excel files were deleted to “avoid unwanted conversation” with the investigators, and add the computers in question are for “personal use to record day to day activities” so there is no impact on product quality. We also acknowledge you performed a product quality impact assessment.\u003C\u002Fp>\u003Cp>Your response is inadequate. Your product quality impact assessment relies, in part, on data generated by your facility’s deficient documentation practices, and therefore is inherently unreliable. Furthermore, you do not adequately evaluate how widespread the practice of record fabrication extends throughout your facility, and you do not share in sufficient detail how you will prevent, detect, and investigate non-contemporaneously prepared records. You also do not adequately explain which, if any records were legitimate and pertain to actual product produced on your equipment. Considering your response states you created records that “falsely attributed” production activities to claim incentives, FDA is concerned about the adequacy of your remediation efforts given you have not sufficiently reconciled all CGMP records.\u003C\u002Fp>\u003Cp>\u003Cstrong>Data Integrity Remediation\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document \u003Cem>Data Integrity and Compliance With Drug CGMP\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fp>\u003Cp>We acknowledge you are using an independent third-party consultant to audit your operation and assist you in meeting FDA requirements.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A full reconciliation of all APIs manufactured at your facility intended for the US market over the past 3 years, including:\u003Cbr>o Name and lot numbers of API manufactured and released.\u003Cbr>o Plant or building identification where the API was made, including date of manufacture.\u003Cbr>o All API or intermediates received and packaged for further distribution from any or your manufacturing plants in the current location.\u003Cbr>o Determination if singular or multiple batch records exist, or if records are incomplete.\u003Cbr>o For each instance of CGMP record anomalies identified by an independent third party, a description of the issue, as well as a detailed root cause and corrective action plan.\u003Cbr>o Status of each employee involved in record fabrication as described above and as part of your investigation, and whether they are currently employed or still performing CGMP functions at your company.\u003C\u002Fli>\u003Cli>A comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\u003Cbr>o A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\u003Cbr>o Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\u003Cbr>o An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\u003Cbr>o A comprehensive retrospective evaluation of the nature of the manufacturing data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all data integrity lapses.\u003C\u002Fli>\u003Cli>A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003C\u002Fli>\u003Cli>A management strategy for your firm that includes the details of your global corrective action and preventive action (CAPA) plan. Your strategy should include:\u003Cbr>o A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate including analytical data, manufacturing records, and all data submitted to FDA.\u003Cbr>o A comprehensive description of the root causes of your data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\u003Cbr>o Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\u003Cbr>o Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\u003Cbr>o A commitment to have a qualified consultant conduct extensive annual audits, for at least 2 years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\u003Cbr>o Inform FDA if you will be hiring a Chief Integrity Officer who is fully empowered to receive anonymous complaints from employees reporting data integrity concerns and with the authority to ensure any potential breach is promptly investigated (by independent quality assurance function, along with expertise from outside entities whenever needed).\u003Cbr>o A status report for any of the above activities already underway or completed.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Failure to properly maintain buildings and facilities used in the manufacture of APIs.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to maintain your facility in an acceptable state of repair. For example, investigators observed a room with \u003Cstrong>(b)(4)\u003C\u002Fstrong> liquid in a floor cavity surrounding the exit pipe of a \u003Cstrong>(b)(4)\u003C\u002Fstrong>. A similar liquid was dripping from a ceiling pipe junction in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> area below this room. The liquid was dripping onto processing equipment labeled as clean and ready for use.\u003C\u002Fp>\u003Cp>It is essential your facility is in a good state of repair, and sanitary conditions are maintained to ensure ongoing suitability for drug manufacturing.\u003C\u002Fp>\u003Cp>In your response, you state no production activities were taking place in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> area, as it was partially shut down to make various upgrades, and you state the damaged flooring has since been repaired. You also state personnel did not display proper signage in the area, as required by your procedure, and a change control had been initiated. Additionally, your deviation report submitted with your response states personnel were not aware of ongoing maintenance activities in Plant \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not sufficiently address potential contamination of previously manufactured lots caused by leaks from the flooring. During the inspection, no information was provided to support a partial shutdown, or that a change control was initiated as indicated in your response. Additionally, you do not adequately evaluate the potential quality impact to previously manufactured lots produced during maintenance shutdowns, and thus outside your standard manufacturing controls. Furthermore, based on your documentation deficiencies, it is unclear whether you manufactured lots of API during partial shutdown activities. You also lack evidence you comprehensively evaluated the state of repair throughout your entire facility.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fli>\u003Cli>A comprehensive evaluation and risk assessment of lots that may have been impacted by leaks from damaged flooring and other facility deficiencies.\u003C\u002Fli>\u003Cli>A list of lots produced on equipment, or in areas, that were in a shutdown status.\u003C\u002Fli>\u003Cli>Your training records and updated procedures to show your staff is aware of procedures related to maintenance and shutdown activities.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Failure to establish an impurity profile for identified and unidentified impurities.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to conduct a comprehensive evaluation of your manufacturing processes to identify all potential impurities. For example, the impurity profile you provided for \u003Cstrong>(b)(4)\u003C\u002Fstrong> USP, only listed those impurities described in the United States Pharmacopeia (USP), without considering your unique processes and materials to describe additional impurities in a typical lot. Furthermore, you failed to sufficiently classify each identified impurity. Our inspection also noted impurities are not monitored during stability studies.\u003C\u002Fp>\u003Cp>In your response, you include impurity profiles and data from forced degradation studies, which you state was provided to investigators on the final day of the inspection. We acknowledge you also include updated impurity profiles with further details completed since the inspection. You also state drug product manufacturers who you supply perform testing of the drug products for impurities, and you have not received any returned APIs due to quality issues.\u003C\u002Fp>\u003Cp>Your response is inadequate. Our inspection found you have received at least two lots of returned product due to quality issues in the last two years. You also received a complaint for one lot of \u003Cstrong>(b)(4)\u003C\u002Fstrong> USP that failed the customer’s identity testing. Furthermore, you do not provide a retroactive risk assessment of distributing APIs with incomplete impurity profiles, and you lack evidence that you communicated your updated impurity profiles to your customers who you state test the drug products for impurities. Additionally, your APIs are distributed to \u003Cstrong>(b)(4)\u003C\u002Fstrong> who typically do not test components for compliance with quality specifications, including impurity testing.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A retrospective review of all API lots released without appropriate testing for impurities and how that may impact finished drug quality.\u003C\u002Fli>\u003Cli>A plan to address any product quality or patient safety risks for out-of-specification lots of APIs in U.S. distribution, including recalls.\u003C\u002Fli>\u003Cli>Specifications, including test methods, used to release APIs. Your response should address your capability to detect and quantify a wide array of potential impurities or contaminants.\u003C\u002Fli>\u003Cli>Improved procedures for performing a systemic evaluation for identifying impurities and establishing a control strategy from the process development stages.\u003C\u002Fli>\u003Cli>Results from release testing of all lots of \u003Cstrong>(b)(4)\u003C\u002Fstrong> USP that remain within the established retest or expiry date.\u003C\u002Fli>\u003Cli>Updated risk assessments for the potential presence of impurities in \u003Cstrong>(b)(4)\u003C\u002Fstrong> USP manufactured at your facility. Include your program for ongoing evaluation of impurity profiles for all drugs and starting materials you produce.\u003C\u002Fli>\u003Cli>Identify corrective actions to ensure adequate quality oversight of establishing appropriate impurity and degradant limits for all drugs and starting materials, you produce, using well-studied, scientifically based impurity profiles specific to their own manufacturing processes.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the deviations we identified at your firm, you should engage a consultant qualified to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPAs before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Additional API CGMP Guidance\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA considers the expectations outlined in ICH Q7 when determining whether API are manufactured in conformance with CGMP. See FDA’s guidance document \u003Cem>Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients\u003C\u002Fem> for guidance regarding CGMP for the manufacture of API at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71518\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\u003Cp>FDA placed products offered for import into the United States from your firm on Import Alert 66-40 on December 20, 2024.\u003C\u002Fp>\u003Cp>Correct any deviations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any deviations.\u003C\u002Fp>\u003Cp>Failure to address any deviations may also result in the FDA continuing to refuse admission of articles manufactured at Global Calcium Pvt. Limited, Tamil Nadu, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We request you email Christina Reyes, Christina.Reyes@fda.hhs.gov, within five days of receipt of this letter to schedule a call with FDA.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. Specify what you have done to address any deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004094136 and ATTN: Matthew Jensen.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>_______________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail - Delivery and Read Receipt Requested\n\nReference #:\n\n320-25-30\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Arif Vazirally\n\nRecipient Title\n\nExecutive Chairman\n\nGlobal Calcium Pvt. Limited\n\nNo. 882, 6th Cross, 6th Block\n\nKoramangala\n\nBengaluru 560095\n\nIndia\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-30\nJanuary 16, 2025\nDear Mr. Vazirally:\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Global Calcium Pvt. Limited, FEI 3004094136, at Bangalore - Hosur Highway, 125\u002F126, Sipcot Industrial Complex, Hosur, Tamil Nadu, India 635126, from July 29 to August 2, 2024.\nThis warning letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for active pharmaceutical ingredients (APIs).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your APIs are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your August 23, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific deviations including, but not limited to, the following.\n1. Failure of your quality unit to prepare, review, and approve documents related to the manufacturing of APIs in accordance with written procedures.\nYou provided production records for two different APIs that showed manufacturing activities occurred simultaneously on the same equipment. For example, your batch records and equipment logbooks show the same equipment including, but not limited to,(b)(4) were used at the same time to manufacture (b)(4) USP and (b)(4) USP.\nAdditionally, you deleted multiple electronic records during the inspection. For example, on the initial morning of the inspection, investigators observed Microsoft Excel documents on a desktop computer in the Plant (b)(4) production office including, but not limited to, “(b)(4) Cleaning validation samples,” “(b)(4) Production Details-2024,” “Plant-(b)(4) production Report Jun-2024,” and “Planning June-2024.” On the second day, investigators returned to the production office to review these files. However, all files had been deleted and could not be recovered during the inspection. Without access to the files, the investigators were unable to determine their purpose and adequately evaluate your adherence to CGMP.\nIn your response, you acknowledge your production head directed the creation of falsified manufacturing records to misrepresent API production activities so incentives could be claimed regarding production in plant (b)(4). Additionally, you state a lack of training and other factors resulted in deficient documentation control, then explain you have revised your SOP for document issuance and control. You also state Microsoft Excel files were deleted to “avoid unwanted conversation” with the investigators, and add the computers in question are for “personal use to record day to day activities” so there is no impact on product quality. We also acknowledge you performed a product quality impact assessment.\nYour response is inadequate. Your product quality impact assessment relies, in part, on data generated by your facility’s deficient documentation practices, and therefore is inherently unreliable. Furthermore, you do not adequately evaluate how widespread the practice of record fabrication extends throughout your facility, and you do not share in sufficient detail how you will prevent, detect, and investigate non-contemporaneously prepared records. You also do not adequately explain which, if any records were legitimate and pertain to actual product produced on your equipment. Considering your response states you created records that “falsely attributed” production activities to claim incentives, FDA is concerned about the adequacy of your remediation efforts given you have not sufficiently reconciled all CGMP records.\nData Integrity Remediation\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\nWe acknowledge you are using an independent third-party consultant to audit your operation and assist you in meeting FDA requirements.\nIn response to this letter, provide:\nA full reconciliation of all APIs manufactured at your facility intended for the US market over the past 3 years, including:\no Name and lot numbers of API manufactured and released.\no Plant or building identification where the API was made, including date of manufacture.\no All API or intermediates received and packaged for further distribution from any or your manufacturing plants in the current location.\no Determination if singular or multiple batch records exist, or if records are incomplete.\no For each instance of CGMP record anomalies identified by an independent third party, a description of the issue, as well as a detailed root cause and corrective action plan.\no Status of each employee involved in record fabrication as described above and as part of your investigation, and whether they are currently employed or still performing CGMP functions at your company.\nA comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\no A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\no Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\no An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\no A comprehensive retrospective evaluation of the nature of the manufacturing data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all data integrity lapses.\nA current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\nA management strategy for your firm that includes the details of your global corrective action and preventive action (CAPA) plan. Your strategy should include:\no A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate including analytical data, manufacturing records, and all data submitted to FDA.\no A comprehensive description of the root causes of your data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\no Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\no Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\no A commitment to have a qualified consultant conduct extensive annual audits, for at least 2 years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\no Inform FDA if you will be hiring a Chief Integrity Officer who is fully empowered to receive anonymous complaints from employees reporting data integrity concerns and with the authority to ensure any potential breach is promptly investigated (by independent quality assurance function, along with expertise from outside entities whenever needed).\no A status report for any of the above activities already underway or completed.\n2. Failure to properly maintain buildings and facilities used in the manufacture of APIs.\nYou failed to maintain your facility in an acceptable state of repair. For example, investigators observed a room with (b)(4) liquid in a floor cavity surrounding the exit pipe of a (b)(4). A similar liquid was dripping from a ceiling pipe junction in the (b)(4) area below this room. The liquid was dripping onto processing equipment labeled as clean and ready for use.\nIt is essential your facility is in a good state of repair, and sanitary conditions are maintained to ensure ongoing suitability for drug manufacturing.\nIn your response, you state no production activities were taking place in the (b)(4) area, as it was partially shut down to make various upgrades, and you state the damaged flooring has since been repaired. You also state personnel did not display proper signage in the area, as required by your procedure, and a change control had been initiated. Additionally, your deviation report submitted with your response states personnel were not aware of ongoing maintenance activities in Plant (b)(4).\nYour response is inadequate. You do not sufficiently address potential contamination of previously manufactured lots caused by leaks from the flooring. During the inspection, no information was provided to support a partial shutdown, or that a change control was initiated as indicated in your response. Additionally, you do not adequately evaluate the potential quality impact to previously manufactured lots produced during maintenance shutdowns, and thus outside your standard manufacturing controls. Furthermore, based on your documentation deficiencies, it is unclear whether you manufactured lots of API during partial shutdown activities. You also lack evidence you comprehensively evaluated the state of repair throughout your entire facility.\nIn response to this letter, provide:\nYour CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\nA comprehensive evaluation and risk assessment of lots that may have been impacted by leaks from damaged flooring and other facility deficiencies.\nA list of lots produced on equipment, or in areas, that were in a shutdown status.\nYour training records and updated procedures to show your staff is aware of procedures related to maintenance and shutdown activities.\n3. Failure to establish an impurity profile for identified and unidentified impurities.\nYou failed to conduct a comprehensive evaluation of your manufacturing processes to identify all potential impurities. For example, the impurity profile you provided for (b)(4) USP, only listed those impurities described in the United States Pharmacopeia (USP), without considering your unique processes and materials to describe additional impurities in a typical lot. Furthermore, you failed to sufficiently classify each identified impurity. Our inspection also noted impurities are not monitored during stability studies.\nIn your response, you include impurity profiles and data from forced degradation studies, which you state was provided to investigators on the final day of the inspection. We acknowledge you also include updated impurity profiles with further details completed since the inspection. You also state drug product manufacturers who you supply perform testing of the drug products for impurities, and you have not received any returned APIs due to quality issues.\nYour response is inadequate. Our inspection found you have received at least two lots of returned product due to quality issues in the last two years. You also received a complaint for one lot of (b)(4) USP that failed the customer’s identity testing. Furthermore, you do not provide a retroactive risk assessment of distributing APIs with incomplete impurity profiles, and you lack evidence that you communicated your updated impurity profiles to your customers who you state test the drug products for impurities. Additionally, your APIs are distributed to (b)(4) who typically do not test components for compliance with quality specifications, including impurity testing.\nIn response to this letter, provide:\nA retrospective review of all API lots released without appropriate testing for impurities and how that may impact finished drug quality.\nA plan to address any product quality or patient safety risks for out-of-specification lots of APIs in U.S. distribution, including recalls.\nSpecifications, including test methods, used to release APIs. Your response should address your capability to detect and quantify a wide array of potential impurities or contaminants.\nImproved procedures for performing a systemic evaluation for identifying impurities and establishing a control strategy from the process development stages.\nResults from release testing of all lots of (b)(4) USP that remain within the established retest or expiry date.\nUpdated risk assessments for the potential presence of impurities in (b)(4) USP manufactured at your facility. Include your program for ongoing evaluation of impurity profiles for all drugs and starting materials you produce.\nIdentify corrective actions to ensure adequate quality oversight of establishing appropriate impurity and degradant limits for all drugs and starting materials, you produce, using well-studied, scientifically based impurity profiles specific to their own manufacturing processes.\nCGMP Consultant Recommended\nBased upon the nature of the deviations we identified at your firm, you should engage a consultant qualified to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPAs before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nAdditional API CGMP Guidance\nFDA considers the expectations outlined in ICH Q7 when determining whether API are manufactured in conformance with CGMP. See FDA’s guidance document Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients for guidance regarding CGMP for the manufacture of API at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71518\u002Fdownload.\nConclusion\nThe deviations cited in this letter are not intended to be an all-inclusive list of deviations that exist at your facility You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\nFDA placed products offered for import into the United States from your firm on Import Alert 66-40 on December 20, 2024.\nCorrect any deviations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any deviations.\nFailure to address any deviations may also result in the FDA continuing to refuse admission of articles manufactured at Global Calcium Pvt. Limited, Tamil Nadu, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nWe request you email Christina Reyes, Christina.Reyes@fda.hhs.gov, within five days of receipt of this letter to schedule a call with FDA.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days1. Specify what you have done to address any deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004094136 and ATTN: Matthew Jensen.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n_______________________________\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Global Calcium Pvt. Limited","global-calcium-pvt-limited-692000-01162025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fglobal-calcium-pvt-limited-692000-01162025","2026-10-26T08:08:46.355337+00:00","Closed Out","2025-02-04","692000","2026-07-30","Mr. Arif Vazirally","2026-08-19T17:02:59.386+00:00","Via Electronic Mail - Delivery and Read Receipt Requested","320-25-30","2025-01-16",{"id":98,"raw":99,"subject":106,"body_html":107,"body_text":108,"firm_name":109,"letter_id":110,"created_at":111,"fei_number":19,"letter_url":112,"updated_at":113,"action_type":22,"case_status":88,"posted_date":114,"marcs_cms_no":115,"product_type":116,"closeout_date":117,"issuing_office":103,"recipient_name":118,"body_fetched_at":119,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":114,"medical_device_id":19,"response_letter_date":19},3492,[100,101,102,103,104,13,105,13],"\u003Ctime datetime=\"2021-03-04T05:17:00Z\">03\u002F04\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-03-04T05:00:00Z\">03\u002F04\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcertify-global-inc-613568-03042021\">Certify Global Inc.\u003C\u002Fa>","Center for Devices and Radiological Health","Device Adulterated and Misbranded\u003Cbr \u002F>\r\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcertify-global-inc-613568-12132024\">\u003Ctime datetime=\"2024-12-17T05:00:00Z\">12\u002F17\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","Device Adulterated and Misbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Marc Potash\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Certify Global Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>9801 Washingtonian Boulevard\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Suite 200\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gaithersburg\u003C\u002Fspan>, \u003Cspan>MD\u003C\u002Fspan> \u003Cspan>20878\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:marc.potash@certifyglobal.com\"> marc.potash@certifyglobal.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>Dear Sir,\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fcertify.me on February 9, 2021. The FDA has observed that your website offers products for measuring human body temperature, specifically the “SNAP XT PRO HID” and “InfinityX PRO” for sale in the United States. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h), the SNAP XT PRO HID and InfinityX PRO are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. Telethermographic systems are devices when they are intended for a medical purpose, such as body temperature measurement, including such use in non-medical environments.\u003C\u002Fp>\n\n\u003Cp>The SNAP XT PRO HID and InfinityX PRO are offered for sale in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, your products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your products are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce these products into interstate commerce for commercial distribution as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a).\u003C\u002Fp>\n\n\u003Cp>Use of telethermographic devices for the assessment of human body temperature can present potentially serious public health risks. Such risks may include, but are not limited to, the device incorrectly detecting a normal human body temperature when a person has an elevated temperature and incorrectly assessing a person to have an elevated body temperature when they do not. A person with an undetected elevated temperature who was subject to temperature assessment using a telethermographic device may, as a result, be less likely to adhere to infection prevention and control guidelines, such as social distancing and using personal protective equipment. These risks are more likely to be present where telethermographic devices scan multiple individuals simultaneously. Your website, https:\u002F\u002Fcertify.me\u002F, includes statements that indicate that the the SNAP XT PRO HID and InfinityX PRO are intended to scan multiple individuals simultaneously, including:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Single and Multi user Scanning” and “Capability :3-4 persons one time” [Published on your website for the SNAP XT PRO HID, https:\u002F\u002Fcertify.me\u002Fproduct\u002Fsnap-xt-pro\u002F]\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cul>\n\t\u003Cli>“Multi-Person Scanning” and “Thermal Reading 7 Simultaneous Reads” [Published on your website for the InfinityX PRO, https:\u002F\u002Fcertify.me\u002Fproduct\u002Fcertify-infinityx-pro\u002F]\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your firm should take prompt action to correct any violations. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.&nbsp;\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. After you receive this letter, please notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to correct any violations, as well as an explanation of how your firm plans to prevent their recurrence.\u003C\u002Fp>\n\n\u003Cp>Your response should include documentation of the corrections and\u002For corrective actions (including those that address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003Cbr>\n&nbsp;\u003Cbr>\nYour firm’s response should be sent to:\u003Cbr>\n&nbsp;\u003Cbr>\nAttn: CAPT Alan Stevens\u003Cbr>\nActing Director, Division of Drug Delivery and General Hospital Devices,\u003Cbr>\nand Human Factors\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nCenter for Devices and Radiological Health\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nOHT3: Office of GastroRenal, ObGyn, General Hospital, and Urology Devices\u003Cbr>\nDocument Control Center (DCC) – WO66-G609\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003Cbr>\n&nbsp;\u003Cbr>\nRefer to the reference number CMS 613568 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Jake Lindstrom, PhD at \u003Ca href=\"mailto:Jake.Lindstrom@fda.hhs.gov\">Jake.Lindstrom@fda.hhs.gov\u003C\u002Fa> or \u003Cspan>(301) 796-5716\u003Ca>\u003C\u002Fa>\u003C\u002Fspan>.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations.\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nSincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nCourtney H. Lias, Ph.D.\u003Cbr>\nActing Office Director\u003Cbr>\nOHT3: Office of GastroRenal, ObGyn,\u003Cbr>\nGeneral Hospital and Urology Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMarc Potash\n\nCertify Global Inc.\n\n9801 Washingtonian Boulevard\n\nSuite 200\n\nGaithersburg, MD 20878\n\nUnited States\n\nmarc.potash@certifyglobal.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nDear Sir,\n\nThis is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fcertify.me on February 9, 2021. The FDA has observed that your website offers products for measuring human body temperature, specifically the “SNAP XT PRO HID” and “InfinityX PRO” for sale in the United States. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h), the SNAP XT PRO HID and InfinityX PRO are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. Telethermographic systems are devices when they are intended for a medical purpose, such as body temperature measurement, including such use in non-medical environments.\n\nThe SNAP XT PRO HID and InfinityX PRO are offered for sale in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, your products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your products are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce these products into interstate commerce for commercial distribution as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a).\n\nUse of telethermographic devices for the assessment of human body temperature can present potentially serious public health risks. Such risks may include, but are not limited to, the device incorrectly detecting a normal human body temperature when a person has an elevated temperature and incorrectly assessing a person to have an elevated body temperature when they do not. A person with an undetected elevated temperature who was subject to temperature assessment using a telethermographic device may, as a result, be less likely to adhere to infection prevention and control guidelines, such as social distancing and using personal protective equipment. These risks are more likely to be present where telethermographic devices scan multiple individuals simultaneously. Your website, https:\u002F\u002Fcertify.me\u002F, includes statements that indicate that the the SNAP XT PRO HID and InfinityX PRO are intended to scan multiple individuals simultaneously, including:\n\n“Single and Multi user Scanning” and “Capability :3-4 persons one time” [Published on your website for the SNAP XT PRO HID, https:\u002F\u002Fcertify.me\u002Fproduct\u002Fsnap-xt-pro\u002F]\n\n“Multi-Person Scanning” and “Thermal Reading 7 Simultaneous Reads” [Published on your website for the InfinityX PRO, https:\u002F\u002Fcertify.me\u002Fproduct\u002Fcertify-infinityx-pro\u002F]\n\nYour firm should take prompt action to correct any violations. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. After you receive this letter, please notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to correct any violations, as well as an explanation of how your firm plans to prevent their recurrence.\n\nYour response should include documentation of the corrections and\u002For corrective actions (including those that address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour firm’s response should be sent to:\n\nAttn: CAPT Alan Stevens\n\nActing Director, Division of Drug Delivery and General Hospital Devices,\n\nand Human Factors\n\nU.S. Food and Drug Administration\n\nCenter for Devices and Radiological Health\n\nOffice of Product Evaluation and Quality\n\nOHT3: Office of GastroRenal, ObGyn, General Hospital, and Urology Devices\n\nDocument Control Center (DCC) – WO66-G609\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nRefer to the reference number CMS 613568 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Jake Lindstrom, PhD at Jake.Lindstrom@fda.hhs.gov or (301) 796-5716.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations.\n\nSincerely,\n\n\u002FS\u002F\n\nCourtney H. Lias, Ph.D.\n\nActing Office Director\n\nOHT3: Office of GastroRenal, ObGyn,\n\nGeneral Hospital and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health","Certify Global Inc.","certify-global-inc-613568-03042021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcertify-global-inc-613568-03042021","2026-10-26T08:08:13.335825+00:00","2021-03-04","613568","Medical Devices","2024-12-17","Marc Potash","2026-08-20T03:18:53.275+00:00",{"id":121,"raw":122,"subject":38,"body_html":127,"body_text":128,"firm_name":129,"letter_id":130,"created_at":131,"fei_number":19,"letter_url":132,"updated_at":133,"action_type":22,"case_status":23,"posted_date":134,"marcs_cms_no":135,"product_type":48,"closeout_date":19,"issuing_office":126,"recipient_name":136,"body_fetched_at":137,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":138,"medical_device_id":19,"response_letter_date":19},2975,[123,124,125,126,38,13,13,13],"\u003Ctime datetime=\"2021-12-14T14:20:00Z\">12\u002F14\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-10-22T04:00:00Z\">10\u002F22\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fitc-global-trading-inc-615409-10222021\">ITC Global Trading Inc.\u003C\u002Fa>","Division of Southwest Imports Compliance Branch","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>John Wong\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>ITC Global Trading Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1505 Sawyer St Ste B\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Houston\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>77007-4425\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Southwest Imports Compliance Branch\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 22, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\n\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Wong:&nbsp;\u003C\u002Fp>\n\n\u003Cp>From April 30 to May 19, 2021, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Programs (FSVP) inspection of ITC Global Trading, Inc located at 1505 Sawyer St Ste B, Houston, Texas. &nbsp;We also conducted inspections on August 4, 2017 and on February 24, 2020. &nbsp;These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. &nbsp;You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\u003C\u002Fp>\n\n\u003Cp>During the most recent inspection, we found that you were not in compliance with the requirements of 21 CFR part 1 subpart L for the following the food you import, Canned Mango and Passion Fruit Drink, Water Chestnuts in Syrup, and Coconut Meat in Syrup. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003Cbr>\nAt the conclusion of the inspection, our investigator provided you with Form FDA 483a, FSVP Observations. &nbsp;We have not received your response to the Form FDA 483a issued on May 19, 2021.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>1.&nbsp;&nbsp; &nbsp;You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). &nbsp;Specifically, you did not develop an FSVP for any of the foods you import, including the following foods:\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;Canned Mango and Passion Fruit Drink imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>\n•&nbsp;&nbsp; &nbsp;Water Chestnuts in Syrup imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>\n•&nbsp;&nbsp; &nbsp;Coconut Meat in Syrup imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>2.&nbsp;&nbsp; &nbsp;For thermally processed low-acid foods packaged in hermetically sealed containers (low-acid canned foods) and with respect to the microbiological hazards associated with these food products, you must verify and document that they were produced in accordance with 21 CFR part 113. &nbsp;Specifically, you did not verify and document that the canned food products you import, including but not limited to Water Chestnuts in Syrup and Coconut Meat in Syrup, were produced in accordance with 21 CFR part 113 (regarding thermally processed low-acid foods packaged in hermetically sealed containers), as required by 21 CFR 1.502(b)(1).\u003C\u002Fp>\n\n\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. &nbsp;It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1 subpart L. &nbsp;\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. &nbsp;If you do not adequately address this matter, we may result in further action. &nbsp;For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. &nbsp; We may place all the food you import into the United States on detention without physical examination (DWPE). &nbsp;You can find DWPE information relating to FSVP in Import Alert # 99-41, at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. &nbsp;In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. &nbsp;Your response should address the specific things you are doing to correct any violations. &nbsp;You should include in your response documentation and information that will assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. &nbsp;If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. &nbsp;If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003Cbr>\n&nbsp;\u003Cbr>\nPlease send your reply to Food and Drug Administration, Attention: &nbsp;Virginia Ramos, Compliance Officer, the Division of Southwest Imports, 216 W. Village Blvd., Suite 107, Laredo, Texas 78041. &nbsp;If you have any questions regarding this letter, you may contact Virginia Ramos via email at Virginia.Ramos@fda.hhs.gov. &nbsp;Please reference CMS # 615409 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003Cbr>\nSincerely,\u003Cbr>\n\u002Fs\u002F\u003Cbr>\nTodd Cato\u003Cbr>\nDirector, Southwest Imports\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nCc:\u003C\u002Fp>\n\n\u003Cp>Mr. Nikom Polvanich, President and Owner\u003Cbr>\n1505 Sawyer St. Ste. B\u003Cbr>\nHouston, TX 77007\u003Cbr>\n\u003Cstrong>(b)(6),(b)(7)(C)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nJohn Wong\n\nRecipient Title\n\nManager\n\nITC Global Trading Inc.\n\n1505 Sawyer St Ste B\n\nHouston, TX 77007-4425\n\nUnited States\n\nIssuing Office:\n\nDivision of Southwest Imports Compliance Branch\n\nUnited States\n\nOctober 22, 2021\n\nWARNING LETTER\n\nDear Mr. Wong:\n\nFrom April 30 to May 19, 2021, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Programs (FSVP) inspection of ITC Global Trading, Inc located at 1505 Sawyer St Ste B, Houston, Texas. We also conducted inspections on August 4, 2017 and on February 24, 2020. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring the most recent inspection, we found that you were not in compliance with the requirements of 21 CFR part 1 subpart L for the following the food you import, Canned Mango and Passion Fruit Drink, Water Chestnuts in Syrup, and Coconut Meat in Syrup. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of the inspection, our investigator provided you with Form FDA 483a, FSVP Observations. We have not received your response to the Form FDA 483a issued on May 19, 2021.\n\nYour significant violations of the FSVP regulation are as follows:\n\n1. You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including the following foods:\n\n• Canned Mango and Passion Fruit Drink imported from (b)(4)\n\n• Water Chestnuts in Syrup imported from (b)(4)\n\n• Coconut Meat in Syrup imported from (b)(4)\n\n2. For thermally processed low-acid foods packaged in hermetically sealed containers (low-acid canned foods) and with respect to the microbiological hazards associated with these food products, you must verify and document that they were produced in accordance with 21 CFR part 113. Specifically, you did not verify and document that the canned food products you import, including but not limited to Water Chestnuts in Syrup and Coconut Meat in Syrup, were produced in accordance with 21 CFR part 113 (regarding thermally processed low-acid foods packaged in hermetically sealed containers), as required by 21 CFR 1.502(b)(1).\n\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1 subpart L.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may result in further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place all the food you import into the United States on detention without physical examination (DWPE). You can find DWPE information relating to FSVP in Import Alert # 99-41, at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that will assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: Virginia Ramos, Compliance Officer, the Division of Southwest Imports, 216 W. Village Blvd., Suite 107, Laredo, Texas 78041. If you have any questions regarding this letter, you may contact Virginia Ramos via email at Virginia.Ramos@fda.hhs.gov. Please reference CMS # 615409 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002Fs\u002F\n\nTodd Cato\n\nDirector, Southwest Imports\n\nCc:\n\nMr. Nikom Polvanich, President and Owner\n\n1505 Sawyer St. Ste. B\n\nHouston, TX 77007\n\n(b)(6),(b)(7)(C)","ITC Global Trading Inc.","itc-global-trading-inc-615409-10222021","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fitc-global-trading-inc-615409-10222021","2026-10-26T08:09:01.571973+00:00","2021-12-14","615409","John Wong","2026-08-20T02:20:46.499+00:00","2021-10-22",{"id":140,"raw":141,"subject":146,"body_html":147,"body_text":148,"firm_name":149,"letter_id":150,"created_at":43,"fei_number":19,"letter_url":151,"updated_at":152,"action_type":22,"case_status":23,"posted_date":153,"marcs_cms_no":154,"product_type":155,"closeout_date":19,"issuing_office":145,"recipient_name":19,"body_fetched_at":156,"delivery_method":157,"recipient_title":19,"reference_number":19,"action_taken_date":153,"medical_device_id":19,"response_letter_date":19},2347,[142,143,144,145,146,13,13,13],"\u003Ctime datetime=\"2022-11-16T15:35:00Z\">11\u002F16\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-11-16T05:00:00Z\">11\u002F16\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmoti-global-645644-11162022\">Moti Global\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Moti Global\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@motiplanet.com\"> info@motiplanet.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:service@motiplanet.com\"> service@motiplanet.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>November 16, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fmotiplanet.com and determined that electronic nicotine delivery system (ENDS) products listed there are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1 and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website https:\u002F\u002Fmotiplanet.com revealed that you manufacture and offer for sale or distribution to customers in the United States the following ENDS products without a marketing authorization order, including for example: MOTI POPI Disposable 1500 Puffs- Lush Ice; MOTI POPI Disposable 1500 Puffs-Juicy Grape; and MOTI POPI Disposable 1500 Puffs-Strawberry.\u003C\u002Fp>\n\n\u003Cp>The ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Additional Considerations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA finds your products particularly concerning because the product labeling and\u002For advertising for the MOTI POPI products (see Exhibits A) are likely to promote use of the products by youth by imitating children’s popsicle treat products (see Exhibits B). FDA is concerned about the rising youth appeal and dramatic rise in youth use of ENDS products. Any efforts to entice youth to use tobacco products are of concern to FDA. Sales of such unauthorized tobacco products are prohibited, and FDA is concerned that your actions likely encourage unlawful sales, maintain or increase youth use, and contribute to the public health and safety concerns associated with ENDS products.\u003C\u002Fp>\n\n\u003Cdiv>  \u003Cimg src=\"https:\u002F\u002Fwww.fda.gov\u002Ffiles\u002F645644%20Popsicle%20Treat.PNG\" alt=\"Popsicle Treat\">\n\n\u003C\u002Fdiv>\n\n\n\u003Cdiv>  \u003Cimg src=\"https:\u002F\u002Fwww.fda.gov\u002Ffiles\u002F645644%20Popsicle%20Treat%202.PNG\" alt=\"Popsicle Treat\">\n\n\u003C\u002Fdiv>\n\n\n\u003Cdiv>  \u003Cimg src=\"https:\u002F\u002Fwww.fda.gov\u002Ffiles\u002F645644%20Popsicle%20Treat%203.PNG\" alt=\"Popsicle\">\n\n\u003C\u002Fdiv>\n\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has not received an application from your firm requesting marketing authorization for the products listed in this Warning Letter. These products and any other new tobacco products on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on these websites, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2201880, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nAnn Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Moti Global\u003Cbr>\n3110 Polaris Ave., STE 24\u003Cbr>\nLas Vegas, NV 89102\u003Cbr>\nwholesale@motiplanet.com\u003Cbr>\nmarketing@motiplanet.com\u003C\u002Fp>\n\n\u003Cp>GoDaddy.com, LLC\u003Cbr>\nabuse@godaddy.com\u003C\u002Fp>\n\n\u003Cp>Shopify, Inc.\u003Cbr>\nabuse@shopify.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nMoti Global\n\nChina\n\ninfo@motiplanet.com\n\nservice@motiplanet.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nNovember 16, 2022\n\nWARNING LETTER\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fmotiplanet.com and determined that electronic nicotine delivery system (ENDS) products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1 and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Fmotiplanet.com revealed that you manufacture and offer for sale or distribution to customers in the United States the following ENDS products without a marketing authorization order, including for example: MOTI POPI Disposable 1500 Puffs- Lush Ice; MOTI POPI Disposable 1500 Puffs-Juicy Grape; and MOTI POPI Disposable 1500 Puffs-Strawberry.\n\nThe ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&C Act.\n\nAdditional Considerations\n\nFDA finds your products particularly concerning because the product labeling and\u002For advertising for the MOTI POPI products (see Exhibits A) are likely to promote use of the products by youth by imitating children’s popsicle treat products (see Exhibits B). FDA is concerned about the rising youth appeal and dramatic rise in youth use of ENDS products. Any efforts to entice youth to use tobacco products are of concern to FDA. Sales of such unauthorized tobacco products are prohibited, and FDA is concerned that your actions likely encourage unlawful sales, maintain or increase youth use, and contribute to the public health and safety concerns associated with ENDS products.\n\nConclusion and Requested Actions\n\nFDA has not received an application from your firm requesting marketing authorization for the products listed in this Warning Letter. These products and any other new tobacco products on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nIt is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on these websites, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2201880, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nMoti Global\n\n3110 Polaris Ave., STE 24\n\nLas Vegas, NV 89102\n\nwholesale@motiplanet.com\n\nmarketing@motiplanet.com\n\nGoDaddy.com, LLC\n\nabuse@godaddy.com\n\nShopify, Inc.\n\nabuse@shopify.com","Moti Global","moti-global-645644-11162022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmoti-global-645644-11162022","2026-10-26T08:09:28.088904+00:00","2022-11-16","645644","Tobacco","2026-08-20T01:26:08.961+00:00","VIA Electronic Mail",{"id":159,"raw":160,"subject":146,"body_html":163,"body_text":164,"firm_name":165,"letter_id":166,"created_at":111,"fei_number":19,"letter_url":167,"updated_at":168,"action_type":22,"case_status":23,"posted_date":169,"marcs_cms_no":170,"product_type":155,"closeout_date":19,"issuing_office":145,"recipient_name":171,"body_fetched_at":172,"delivery_method":173,"recipient_title":19,"reference_number":174,"action_taken_date":169,"medical_device_id":19,"response_letter_date":19},3107,[161,161,162,145,146,13,13,13],"\u003Ctime datetime=\"2021-10-07T13:00:00Z\">10\u002F07\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fjmjl-global-llc-618807-10072021\">JMJL Global LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>RW2101652\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>David Lee\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>JMJL Global LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2821 Saturn Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Unit B\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Brea\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92821\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:brewellvapory@gmail.com\"> brewellvapory@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@brewellmfg.com\"> info@brewellmfg.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>Dear David Lee:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.brewellmfg.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquids are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. &nbsp;Therefore, e-liquid products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. &nbsp;See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. &nbsp;A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). &nbsp;Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website https:\u002F\u002Fwww.brewellmfg.com revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products without a marketing authorization order including: e-liquid products Brewell Tobacco Series - Butterscotch #5, Brewell - Hard Strawberry #22, and Brewell - Melon Breeze #23.&nbsp;\u003C\u002Fp>\n\n\u003Cp>The e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. &nbsp;These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. &nbsp;Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. &nbsp;In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&amp;C Act. &nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>&nbsp;\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 200 products listed with FDA. &nbsp;FDA received your Premarket Tobacco Product Applications (PMTAs) assigned STNs PM0001206, PM0001207, and PM0001216 on September 7, 2020. &nbsp;However, FDA issued negative actions for PMTA STNs PM0001206, PM0001207, and PM0001216 in the form of Marketing Denial Order determinations on September 8, 2021, which cover seven products. &nbsp;As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your e-liquid products covered by PMTA STNs PM0001206, PM0001207, and PM0001216 that resulted in No Marketing Order determinations, are adulterated and misbranded.&nbsp;\u003C\u002Fp>\n\n\u003Cp>All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. &nbsp;Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. &nbsp;For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market. &nbsp;&nbsp;\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. &nbsp;Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. &nbsp;However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. &nbsp;Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. &nbsp;You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. &nbsp;If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. &nbsp;This letter notifies you of our findings and provides you with an opportunity to address them. &nbsp;You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2101652, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:&nbsp;\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement&nbsp;\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov. &nbsp; &nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nSincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nAnn Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement&nbsp;\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\n\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>GoDaddy.com, LLC\u003Cbr>\nabuse@godaddy.com&nbsp;\u003C\u002Fp>\n\n\u003Cp>Shopify, Inc.\u003Cbr>\nabuse@shopify.com&nbsp;\u003C\u002Fp>\n\n\u003Cp>JMJL Global, Inc.\u003Cbr>\nAttn: Young Lee\u003Cbr>\n565 W. Lambert Rd., Unit B&nbsp;\u003Cbr>\nBrea, CA 92821\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nRW2101652\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nDavid Lee\n\nJMJL Global LLC\n\n2821 Saturn Street\n\nUnit B\n\nBrea, CA 92821\n\nUnited States\n\nbrewellvapory@gmail.com\n\ninfo@brewellmfg.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nDear David Lee:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.brewellmfg.com and determined that the e-liquid products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquids are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, e-liquid products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, ENDS (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Fwww.brewellmfg.com revealed that you manufacture and offer for sale or distribution to customers in the United States e-liquid products without a marketing authorization order including: e-liquid products Brewell Tobacco Series - Butterscotch #5, Brewell - Hard Strawberry #22, and Brewell - Melon Breeze #23.\n\nThe e-liquid products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products were not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 200 products listed with FDA. FDA received your Premarket Tobacco Product Applications (PMTAs) assigned STNs PM0001206, PM0001207, and PM0001216 on September 7, 2020. However, FDA issued negative actions for PMTA STNs PM0001206, PM0001207, and PM0001216 in the form of Marketing Denial Order determinations on September 8, 2021, which cover seven products. As discussed above, new tobacco products that do not have the required FDA marketing authorization order in effect, including your e-liquid products covered by PMTA STNs PM0001206, PM0001207, and PM0001216 that resulted in No Marketing Order determinations, are adulterated and misbranded.\n\nAll new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion. Products for which no application is pending, including, for example, those with a Marketing Denial Order and those for which no application was submitted, are among our highest enforcement priorities. For information on how FDA intends to prioritize enforcement resources with regard to the marketing of certain adulterated and misbranded ENDS and other deemed new tobacco products, please refer to the FDA’s guidance titled Enforcement Priorities for Electronic Nicotine Delivery Systems (ENDS) and Other Deemed Products on the Market Without Premarket Authorization, available at https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fenforcement-priorities-electronic-nicotine-delivery-system-ends-and-other-deemed-products-market.\n\nIt is your responsibility to ensure that all of your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2101652, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Ele Ibarra-Pratt at (301) 796-9235 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nGoDaddy.com, LLC\n\nabuse@godaddy.com\n\nShopify, Inc.\n\nabuse@shopify.com\n\nJMJL Global, Inc.\n\nAttn: Young Lee\n\n565 W. Lambert Rd., Unit B\n\nBrea, CA 92821","JMJL Global LLC","jmjl-global-llc-618807-10072021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fjmjl-global-llc-618807-10072021","2026-10-26T08:09:04.669214+00:00","2021-10-07","618807","David Lee","2026-08-20T02:33:22.5+00:00","VIA UPS and Electronic Mail","RW2101652",{"id":176,"raw":177,"subject":38,"body_html":182,"body_text":183,"firm_name":184,"letter_id":185,"created_at":43,"fei_number":19,"letter_url":186,"updated_at":187,"action_type":22,"case_status":23,"posted_date":188,"marcs_cms_no":189,"product_type":48,"closeout_date":19,"issuing_office":181,"recipient_name":190,"body_fetched_at":191,"delivery_method":192,"recipient_title":19,"reference_number":19,"action_taken_date":193,"medical_device_id":19,"response_letter_date":19},2471,[178,179,180,181,38,13,13,13],"\u003Ctime datetime=\"2022-09-06T13:20:00Z\">09\u002F06\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-08-08T04:00:00Z\">08\u002F08\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmina-global-trading-corp-636140-08082022\">Mina Global Trading Corp\u003C\u002Fa>","Division of Northeast Imports","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL AND UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>John Gharghoury\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Mina Global Trading Corp\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>53 Idaho Ln\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Matawan\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07747-1530\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Northeast Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>August 8, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>RE: CMS # 636140\u003C\u002Fp>\n\n\u003Cp>Dear Mr. John Gharghoury:\u003C\u002Fp>\n\n\u003Cp>On April 22 through May 10, 2022, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Mina Global Trading Corp, located at 53 Idaho Ln, Matawan, NJ 07747-1530. We also conducted an inspection on April 12 through April 19, 2021. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspections, our investigator provided you with a Form FDA 483a, FSVP Observations.\u003C\u002Fp>\n\n\u003Cp>During our inspection, you indicated you choose to comply with the requirements for very small importers, and you provided our investigator documentation that you meet the definition of very small importer in 21 CFR 1.500. As a very small importer, you are required to comply with the requirements in sections 1.502, 1.503, 1.509, and 1.512, but you are not required to comply with the requirements in sections 1.504 through 1.508 or 1.510. In addition, for each food you import, you must obtain written assurance, before importing the food and at least every two years thereafter, that your foreign supplier is producing the food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 418 or 419 of the FD&amp;C Act, if either is applicable, and the implementing regulations, and is producing the food in compliance with sections 402 and 403(w) (if applicable) of the FD&amp;C Act (21 CFR 1.512(b)(3)(i)).\u003C\u002Fp>\n\n\u003Cp>We have not received your response to the Form FDA 483a issued on May 10, 2022.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>As a very small importer, for each food you import, you did not obtain written assurance in accordance with 21 CFR 1.512(b)(3), before importing the food and at least every two years thereafter, that your foreign supplier is producing the food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 418 or 419 of the FD&amp;C Act, if either is applicable, and the implementing regulations, and is producing the food in compliance with sections 402 and 403(w) (if applicable) of the FD&amp;C Act. During our inspection you told our investigator you did not have FSVP documents, including written assurances, for any of the food products you import, including your wafers with chocolate and sesame bars from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong> and feta cheese from&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>You may find information on documenting your eligibility as a very small importer and the other requirements under 21 CFR 1.512 in the “Draft Guidance for Industry Foreign Supplier Verification Programs for Imports of Food for Human and Animals” at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fdraft-guidance-industry-foreign-supplier-verification-programs-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fdraft-guidance-industry-foreign-supplier-verification-programs-importers-food-humans-and-animals\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods from the identified foreign suppliers on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at \u003Ca href=\"https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcmsia\u002Fialist.html\">https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcmsia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct these violations. You should include in your response documentation and information that would assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP, and any additional information that you wish to supply relevant to your compliance with the FSVP regulation). If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will address any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Russell Vandermark, FDA Compliance Officer, Division of Northeast Imports: ORAOEIONEIMPORTSWLResponses@fda.hhs.gov. Please also cc (carbon copy) Russell.Vandermark@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Vandermark via email at Russell.Vandermark@fda.hhs.gov. Please reference CMS # 636140 on any documents or records you provide to us and\u002For within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Anna Alexander\u003Cbr>\nActing Program Division Director\u003Cbr>\nDivision of Northeast Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL AND UNITED PARCEL SERVICE\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nJohn Gharghoury\n\nRecipient Title\n\nOwner\n\nMina Global Trading Corp\n\n53 Idaho Ln\n\nMatawan, NJ 07747-1530\n\nUnited States\n\nIssuing Office:\n\nDivision of Northeast Imports\n\nUnited States\n\nAugust 8, 2022\n\nWARNING LETTER\n\nRE: CMS # 636140\n\nDear Mr. John Gharghoury:\n\nOn April 22 through May 10, 2022, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Mina Global Trading Corp, located at 53 Idaho Ln, Matawan, NJ 07747-1530. We also conducted an inspection on April 12 through April 19, 2021. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of the inspections, our investigator provided you with a Form FDA 483a, FSVP Observations.\n\nDuring our inspection, you indicated you choose to comply with the requirements for very small importers, and you provided our investigator documentation that you meet the definition of very small importer in 21 CFR 1.500. As a very small importer, you are required to comply with the requirements in sections 1.502, 1.503, 1.509, and 1.512, but you are not required to comply with the requirements in sections 1.504 through 1.508 or 1.510. In addition, for each food you import, you must obtain written assurance, before importing the food and at least every two years thereafter, that your foreign supplier is producing the food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 418 or 419 of the FD&C Act, if either is applicable, and the implementing regulations, and is producing the food in compliance with sections 402 and 403(w) (if applicable) of the FD&C Act (21 CFR 1.512(b)(3)(i)).\n\nWe have not received your response to the Form FDA 483a issued on May 10, 2022.\n\nYour significant violations of the FSVP regulation are as follows:\n\nAs a very small importer, for each food you import, you did not obtain written assurance in accordance with 21 CFR 1.512(b)(3), before importing the food and at least every two years thereafter, that your foreign supplier is producing the food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 418 or 419 of the FD&C Act, if either is applicable, and the implementing regulations, and is producing the food in compliance with sections 402 and 403(w) (if applicable) of the FD&C Act. During our inspection you told our investigator you did not have FSVP documents, including written assurances, for any of the food products you import, including your wafers with chocolate and sesame bars from (b)(4), located in (b)(4) and feta cheese from (b)(4), located in (b)(4).\n\nYou may find information on documenting your eligibility as a very small importer and the other requirements under 21 CFR 1.512 in the “Draft Guidance for Industry Foreign Supplier Verification Programs for Imports of Food for Human and Animals” at: https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fdraft-guidance-industry-foreign-supplier-verification-programs-importers-food-humans-and-animals\n\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1 subpart L.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods from the identified foreign suppliers on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcmsia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act.\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct these violations. You should include in your response documentation and information that would assist us in evaluating your corrections, (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP, and any additional information that you wish to supply relevant to your compliance with the FSVP regulation). If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will address any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: Russell Vandermark, FDA Compliance Officer, Division of Northeast Imports: ORAOEIONEIMPORTSWLResponses@fda.hhs.gov. Please also cc (carbon copy) Russell.Vandermark@fda.hhs.gov. If you have any questions regarding this letter, you may contact Compliance Officer Vandermark via email at Russell.Vandermark@fda.hhs.gov. Please reference CMS # 636140 on any documents or records you provide to us and\u002For within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nAnna Alexander\n\nActing Program Division Director\n\nDivision of Northeast Imports","Mina Global Trading Corp","mina-global-trading-corp-636140-08082022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmina-global-trading-corp-636140-08082022","2026-10-26T08:09:25.990461+00:00","2022-09-06","636140","John Gharghoury","2026-08-20T01:36:55.521+00:00","VIA EMAIL AND UNITED PARCEL SERVICE","2022-08-08",{"id":195,"raw":196,"subject":146,"body_html":201,"body_text":202,"firm_name":203,"letter_id":204,"created_at":64,"fei_number":19,"letter_url":205,"updated_at":206,"action_type":22,"case_status":23,"posted_date":207,"marcs_cms_no":208,"product_type":155,"closeout_date":19,"issuing_office":145,"recipient_name":209,"body_fetched_at":210,"delivery_method":173,"recipient_title":19,"reference_number":19,"action_taken_date":207,"medical_device_id":19,"response_letter_date":19},1738,[197,198,199,145,200,13,13,13],"\u003Ctime datetime=\"2023-11-16T20:00:00Z\">11\u002F16\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-11-16T05:00:00Z\">11\u002F16\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsweis-global-llc-667364-11162023\">Sweis Global LLC\u003C\u002Fa>","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded\u003Cbr \u002F>\r\n","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Johny H. Sweis\u002FHaitham Sweis\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u002FOwner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Sweis Global LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>7230 Bellaire Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>North Hollywood\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91605\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:johny@puretobacco.com\"> johny@puretobacco.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>November 16, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Johny H. Sweis and Mr. Haitham Sweis:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed our inspection records, and determined that Sweis Global LLC manufactures and distributes hookah tobacco products for commercial distribution in the United States, and that the hookah tobacco products are manufactured and offered for sale or distribution to customers in the United States.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including hookah tobacco products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. &nbsp;See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. &nbsp;Tobacco products, including hookah tobacco products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. &nbsp;For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. &nbsp;A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). &nbsp;Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\u003C\u002Fstrong>&nbsp;\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States hookah tobacco products without a marketing authorization order, including: FML PURE TOBACCO 250 g (Green Label).&nbsp;\u003C\u002Fp>\n\n\u003Cp>The hookah tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act. The introduction or delivery for introduction into interstate commerce of any tobacco product that is adulterated or misbranded is a prohibited act under section 301(a) of the FD&amp;C Act (21 U.S.C. § 331(a)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>&nbsp;\u003C\u002Fp>\n\n\u003Cp>FDA has not received an application from your firm requesting marketing authorization for the product listed in this Warning Letter. This product and any other new tobacco product on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2300985, in your response and direct your response to the following address:&nbsp;\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement&nbsp;\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nAnn Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement&nbsp;\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nJohny H. Sweis\u002FHaitham Sweis\n\nRecipient Title\n\nCEO\u002FOwner\n\nSweis Global LLC\n\n7230 Bellaire Avenue\n\nNorth Hollywood, CA 91605\n\nUnited States\n\njohny@puretobacco.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nNovember 16, 2023\n\nWARNING LETTER\n\nDear Mr. Johny H. Sweis and Mr. Haitham Sweis:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed our inspection records, and determined that Sweis Global LLC manufactures and distributes hookah tobacco products for commercial distribution in the United States, and that the hookah tobacco products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including hookah tobacco products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including hookah tobacco products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nA New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States hookah tobacco products without a marketing authorization order, including: FML PURE TOBACCO 250 g (Green Label).\n\nThe hookah tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act. The introduction or delivery for introduction into interstate commerce of any tobacco product that is adulterated or misbranded is a prohibited act under section 301(a) of the FD&C Act (21 U.S.C. § 331(a)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nFDA has not received an application from your firm requesting marketing authorization for the product listed in this Warning Letter. This product and any other new tobacco product on the market without the statutorily required premarket authorization are adulterated and misbranded and are subject to enforcement action at FDA’s discretion.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., Chapter IX, relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2300985, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","Sweis Global LLC","sweis-global-llc-667364-11162023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsweis-global-llc-667364-11162023","2026-10-26T08:10:08.702715+00:00","2023-11-16","667364","Johny H. Sweis\u002FHaitham Sweis","2026-08-20T00:30:56.145+00:00",{"id":212,"raw":213,"subject":38,"body_html":217,"body_text":218,"firm_name":219,"letter_id":220,"created_at":111,"fei_number":19,"letter_url":221,"updated_at":222,"action_type":22,"case_status":23,"posted_date":223,"marcs_cms_no":224,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":225,"body_fetched_at":226,"delivery_method":227,"recipient_title":19,"reference_number":19,"action_taken_date":228,"medical_device_id":19,"response_letter_date":19},3299,[214,215,216,37,38,13,13,13],"\u003Ctime datetime=\"2021-06-22T13:20:00Z\">06\u002F22\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-04-15T04:00:00Z\">04\u002F15\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdaisy-global-trading-co-612999-04152021\">Daisy Global Trading Co\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Seung Won Baek\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u002FCEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Daisy Global Trading Co\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>17777 Center Court Dr. N Ste 600\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Cerritos\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>90703-8575\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of West Coast Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>April 15, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Re: CMS # 612999\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Seung Won Baek:\u003C\u002Fp>\n\n\u003Cp>From November 18 through December 4, 2020, the Food and Drug Administration (FDA) conducted a remote Foreign Supplier Verification Program (FSVP) inspection of Daisy Global Trading Co. located at 17777 Center Court Dr. N Ste 600, Cerritos, CA 90703-8575. We also conducted an inspection on February 8, 2019. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation under 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for your frozen oriental style udon imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>; fresh Japanese style soba and fresh Japanese style udon imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>; rice sticks imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>; scorched rice imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>; Buckwheat noodle (Zaru soba) imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and Korean seasoned seaweed imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Because of these significant issues, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of both the initial FSVP inspection on February 8, 2019 and the follow-up inspection on December 4, 2020, our investigator provided you in each instance with a Form FDA 483a, FSVP Observations.\u003C\u002Fp>\n\n\u003Cp>We acknowledge receipt of your response, dated December 29, 2020, in which you provided your written procedure regarding FSVPs for your imported products. Enclosed were six (6) FSVPs for the following foods: frozen oriental style udon, fresh Japanese style udon, roasted seasoned seaweed (Laver), Buckwheat noodle (Zaru Soba), scorched rice, and Korean biscuit (Rice stick). During the inspection, you also provided your firm’s FSVP Manual that addressed the documents required from your foreign suppliers: Supplier Letter of Guarantee, Supplier Approval Questionnaire, Hazard Analysis and Critical Control Points (HACCP) Plan, Liability Insurance, and Certificate of 3rd Party Audit. Your FSVP manual also listed the documents your firm must complete and verify for your foreign suppliers: Foreign Supplier Verification Activity Worksheet, FSVP Food Hazard Analysis Form, FSVP Foreign Supplier Evaluation Form, FSVP Supplier Re-evaluation Form, and FSVP Supplier List for Daisy Global Trading. Our review of your response finds that you have not addressed all the violations related to the food products you import, as further described in this letter.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>1. You did not meet the requirement to conduct and document (or obtain documentation of) one or more of the supplier verification activities listed in 21 CFR 1.506(e)(1)(i) through (iv) for each foreign supplier before importing the food and periodically thereafter as required by 21 CFR 1.506(e). Your December 29, 2020 response included six documents titled “FSVP-Foreign Supplier Evaluation.” You did not conduct and document or obtain documentation of one or more supplier verification activities before importing rice sticks imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>; scorched rice imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>; Buckwheat noodle (Zaru soba) imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and Korean seasoned seaweed imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, all located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You also did not provide your documentation of the frequency with which the verification activity will be conducted, as required by 21 CFR 1.506(c).\u003C\u002Fp>\n\n\u003Cp>2. You did not provide your documentation of the corrective action implementation, as required by 21 CFR 1.508. In your December 29, 2020 response, your document titled “FSVP-Foreign Supplier Evaluation” for your rice stick imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong> includes a description under “corrective action needed” of “HACCP Plan, HA &amp; PC, Allergen control Program Required”. Further, your hazard analysis identified allergens as a chemical hazard with justification stated as the product is processed in a facility that also processes peanut, egg, fish, tree nut, wheat, milk, and soybean. However, you have not verified that the supplier has an allergen control program in place. You did not document your corrective action implementation, as required by 21 CFR 1.508.\u003C\u002Fp>\n\n\u003Cp>The above matters are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1 subpart L.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food products you import that appear to be in violation of section 805. We may place the foods you import on detention without physical examination (DWPE) when you import the products. You can find DWPE information relating to FSVP in Import Alert #99-41 at \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your revised FSVP, records to demonstrate implementation of your FSVP, and any additional information that you wish to supply relevant to your compliance with the FSVP regulation). If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Debbie Giang, Compliance Officer, Division of West Coast Imports, One World Trade Center, Suite 300, Long Beach, CA 90831. If you have any questions regarding this letter, you may contact Debbie Giang via phone at (562) 256-9235 or via email at debbie.giang@fda.hhs.gov. Please reference CMS #612999 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Lawton W. Lum\u003Cbr>\nActing Program Division Director\u003Cbr>\nDivision of West Coast Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nSeung Won Baek\n\nRecipient Title\n\nPresident\u002FCEO\n\nDaisy Global Trading Co\n\n17777 Center Court Dr. N Ste 600\n\nCerritos, CA 90703-8575\n\nUnited States\n\nIssuing Office:\n\nDivision of West Coast Imports\n\nUnited States\n\nApril 15, 2021\n\nWarning Letter\n\nRe: CMS # 612999\n\nDear Mr. Seung Won Baek:\n\nFrom November 18 through December 4, 2020, the Food and Drug Administration (FDA) conducted a remote Foreign Supplier Verification Program (FSVP) inspection of Daisy Global Trading Co. located at 17777 Center Court Dr. N Ste 600, Cerritos, CA 90703-8575. We also conducted an inspection on February 8, 2019. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation under 21 CFR part 1 subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1 subpart L for your frozen oriental style udon imported from (b)(4), located in (b)(4); fresh Japanese style soba and fresh Japanese style udon imported from (b)(4), located in (b)(4); rice sticks imported from (b)(4), located in (b)(4); scorched rice imported from (b)(4) located in (b)(4); Buckwheat noodle (Zaru soba) imported from (b)(4) located in (b)(4); and Korean seasoned seaweed imported from (b)(4) located in (b)(4). Because of these significant issues, you are not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of both the initial FSVP inspection on February 8, 2019 and the follow-up inspection on December 4, 2020, our investigator provided you in each instance with a Form FDA 483a, FSVP Observations.\n\nWe acknowledge receipt of your response, dated December 29, 2020, in which you provided your written procedure regarding FSVPs for your imported products. Enclosed were six (6) FSVPs for the following foods: frozen oriental style udon, fresh Japanese style udon, roasted seasoned seaweed (Laver), Buckwheat noodle (Zaru Soba), scorched rice, and Korean biscuit (Rice stick). During the inspection, you also provided your firm’s FSVP Manual that addressed the documents required from your foreign suppliers: Supplier Letter of Guarantee, Supplier Approval Questionnaire, Hazard Analysis and Critical Control Points (HACCP) Plan, Liability Insurance, and Certificate of 3rd Party Audit. Your FSVP manual also listed the documents your firm must complete and verify for your foreign suppliers: Foreign Supplier Verification Activity Worksheet, FSVP Food Hazard Analysis Form, FSVP Foreign Supplier Evaluation Form, FSVP Supplier Re-evaluation Form, and FSVP Supplier List for Daisy Global Trading. Our review of your response finds that you have not addressed all the violations related to the food products you import, as further described in this letter.\n\nYour significant violations of the FSVP regulation are as follows:\n\n1. You did not meet the requirement to conduct and document (or obtain documentation of) one or more of the supplier verification activities listed in 21 CFR 1.506(e)(1)(i) through (iv) for each foreign supplier before importing the food and periodically thereafter as required by 21 CFR 1.506(e). Your December 29, 2020 response included six documents titled “FSVP-Foreign Supplier Evaluation.” You did not conduct and document or obtain documentation of one or more supplier verification activities before importing rice sticks imported from (b)(4); scorched rice imported from (b)(4); Buckwheat noodle (Zaru soba) imported from (b)(4); and Korean seasoned seaweed imported from (b)(4), all located in (b)(4). You also did not provide your documentation of the frequency with which the verification activity will be conducted, as required by 21 CFR 1.506(c).\n\n2. You did not provide your documentation of the corrective action implementation, as required by 21 CFR 1.508. In your December 29, 2020 response, your document titled “FSVP-Foreign Supplier Evaluation” for your rice stick imported from (b)(4) includes a description under “corrective action needed” of “HACCP Plan, HA & PC, Allergen control Program Required”. Further, your hazard analysis identified allergens as a chemical hazard with justification stated as the product is processed in a facility that also processes peanut, egg, fish, tree nut, wheat, milk, and soybean. However, you have not verified that the supplier has an allergen control program in place. You did not document your corrective action implementation, as required by 21 CFR 1.508.\n\nThe above matters are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1 subpart L.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food products you import that appear to be in violation of section 805. We may place the foods you import on detention without physical examination (DWPE) when you import the products. You can find DWPE information relating to FSVP in Import Alert #99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your revised FSVP, records to demonstrate implementation of your FSVP, and any additional information that you wish to supply relevant to your compliance with the FSVP regulation). If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: Debbie Giang, Compliance Officer, Division of West Coast Imports, One World Trade Center, Suite 300, Long Beach, CA 90831. If you have any questions regarding this letter, you may contact Debbie Giang via phone at (562) 256-9235 or via email at debbie.giang@fda.hhs.gov. Please reference CMS #612999 on any documents or records you provide to us and\u002F or within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nLawton W. Lum\n\nActing Program Division Director\n\nDivision of West Coast Imports","Daisy Global Trading Co","daisy-global-trading-co-612999-04152021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdaisy-global-trading-co-612999-04152021","2026-10-26T08:08:21.077549+00:00","2021-06-22","612999","Seung Won Baek","2026-08-20T03:03:29.851+00:00","United Parcel Service","2021-04-15",{"id":230,"raw":231,"subject":146,"body_html":235,"body_text":236,"firm_name":237,"letter_id":238,"created_at":239,"fei_number":19,"letter_url":240,"updated_at":241,"action_type":22,"case_status":23,"posted_date":242,"marcs_cms_no":243,"product_type":155,"closeout_date":19,"issuing_office":145,"recipient_name":19,"body_fetched_at":244,"delivery_method":173,"recipient_title":19,"reference_number":245,"action_taken_date":246,"medical_device_id":19,"response_letter_date":19},239,[232,233,234,145,146,13,13,13],"\u003Ctime datetime=\"2026-04-07T04:00:00Z\">04\u002F07\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-03-31T04:00:00Z\">03\u002F31\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fglobal-tobacco-llc-725103-03312026\">Global Tobacco, LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>ER2601437\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Global Tobacco, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2861 Congressman Lane, Suite 300\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Dallas\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75220\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>March 31, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>To Whom It May Concern:\u003C\u002Fp>\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that Global Tobacco, LLC imports, sells and\u002For distributes nicotine pouch products to customers in the United States.\u003C\u002Fp>\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including nicotine pouch products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including nicotine pouch products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that you import and offer for sale or distribution to customers in the United States the following nicotine pouch products that lack a marketing authorization order: RUSH Mango Freeze 12MG.\u003C\u002Fp>\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\u003C\u002Fp>\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\u003Cp>Please note your reference number, ER2601437, in your response and direct your response to the following address:\u003C\u002Fp>\u003Cp>DEM-WL Response, Office of Compliance and Enforcement&nbsp;&nbsp;\u003Cbr>FDA Center for Tobacco Products&nbsp;&nbsp;\u003Cbr>c\u002Fo Document Control Center&nbsp;&nbsp;\u003Cbr>Building 71, Room G335&nbsp;&nbsp;\u003Cbr>10903 New Hampshire Avenue&nbsp;&nbsp;\u003Cbr>Silver Spring, MD 20993-0002\u003C\u002Fp>\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>John E. Verbeten\u003Cbr>Director\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Center for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nER2601437\n\nProduct:\n\nTobacco\n\nRecipient:\n\nGlobal Tobacco, LLC\n\n2861 Congressman Lane, Suite 300\n\nDallas, TX 75220\n\nUnited States\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nMarch 31, 2026\nWARNING LETTER\nTo Whom It May Concern:\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that Global Tobacco, LLC imports, sells and\u002For distributes nicotine pouch products to customers in the United States.\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including nicotine pouch products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including nicotine pouch products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\nFDA has determined that you import and offer for sale or distribution to customers in the United States the following nicotine pouch products that lack a marketing authorization order: RUSH Mango Freeze 12MG.\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act.\nConclusion and Requested Actions\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\nPlease note your reference number, ER2601437, in your response and direct your response to the following address:\nDEM-WL Response, Office of Compliance and Enforcement\nFDA Center for Tobacco Products\nc\u002Fo Document Control Center\nBuilding 71, Room G335\n10903 New Hampshire Avenue\nSilver Spring, MD 20993-0002\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nJohn E. Verbeten\nDirector\nOffice of Compliance and Enforcement\nCenter for Tobacco Products","Global Tobacco, LLC","global-tobacco-llc-725103-03312026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fglobal-tobacco-llc-725103-03312026","2026-10-26T08:08:46.886633+00:00","2026-04-07","725103","2026-08-19T04:48:47.202+00:00","ER2601437","2026-03-31",{"id":248,"raw":249,"subject":38,"body_html":253,"body_text":254,"firm_name":255,"letter_id":256,"created_at":43,"fei_number":19,"letter_url":257,"updated_at":258,"action_type":22,"case_status":23,"posted_date":259,"marcs_cms_no":260,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":261,"body_fetched_at":262,"delivery_method":263,"recipient_title":19,"reference_number":19,"action_taken_date":264,"medical_device_id":19,"response_letter_date":19},2182,[250,251,252,37,38,13,13,13],"\u003Ctime datetime=\"2023-02-28T14:20:00Z\">02\u002F28\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-10-27T04:00:00Z\">10\u002F27\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftitans-global-inc-642601-10272022\">Titans Global Inc.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                      \u003Cbr>United Parcel Service\n                                                                          \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Yue Wu\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Titans Global Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>15339 Don Julian Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>City Of Industry\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>91745-1034\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of West Coast Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 27, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Re: CMS # 642601\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Wu:\u003C\u002Fp>\n\n\u003Cp>On July 20, 2022 to August 2, 2022, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Titans Global Inc. located at 15339 Don Julian Road, City Of Industry, CA 91745. We also conducted an inspection on May 4, 2021. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, your firm is not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, our investigator provided you with a Form FDA 483a, FSVP Observations. We have not received your response to the Form FDA 483a issued on August 2, 2022.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including each of the following food products:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Cake Original, imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Dried Plum, imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Chili Paste, imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Hot &amp; Sour Instant Noodle W Soup Base, imported from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Juliane Jung-Lau, Compliance Officer, Division of West Coast Imports, 1201 Harbor Bay Parkway, Alameda, CA 94502, with a copy via electronic mail to WCID@fda.hhs.gov. If you have any questions regarding this letter, you may contact Ms. Jung-Lau via email at Juliane.Jung-Lau@fda.hhs.gov. Please reference CMS # 642601 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Dr. Kathleen Turner\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of West Coast Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nUnited Parcel Service\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nYue Wu\n\nRecipient Title\n\nCEO\n\nTitans Global Inc.\n\n15339 Don Julian Road\n\nCity Of Industry, CA 91745-1034\n\nUnited States\n\nIssuing Office:\n\nDivision of West Coast Imports\n\nUnited States\n\nOctober 27, 2022\n\nWARNING LETTER\n\nRe: CMS # 642601\n\nDear Mr. Wu:\n\nOn July 20, 2022 to August 2, 2022, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Titans Global Inc. located at 15339 Don Julian Road, City Of Industry, CA 91745. We also conducted an inspection on May 4, 2021. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, your firm is not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of the inspection, our investigator provided you with a Form FDA 483a, FSVP Observations. We have not received your response to the Form FDA 483a issued on August 2, 2022.\n\nYour significant violations of the FSVP regulation are as follows:\n\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including each of the following food products:\n\n(b)(4) Cake Original, imported from (b)(4), in (b)(4)\n\nDried Plum, imported from (b)(4), in (b)(4)\n\nChili Paste, imported from (b)(4), in (b)(4)\n\nHot & Sour Instant Noodle W Soup Base, imported from (b)(4), in (b)(4)\n\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: Juliane Jung-Lau, Compliance Officer, Division of West Coast Imports, 1201 Harbor Bay Parkway, Alameda, CA 94502, with a copy via electronic mail to WCID@fda.hhs.gov. If you have any questions regarding this letter, you may contact Ms. Jung-Lau via email at Juliane.Jung-Lau@fda.hhs.gov. Please reference CMS # 642601 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nDr. Kathleen Turner\n\nProgram Division Director\n\nDivision of West Coast Imports","Titans Global Inc.","titans-global-inc-642601-10272022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftitans-global-inc-642601-10272022","2026-10-26T08:10:12.70216+00:00","2023-02-28","642601","Yue Wu","2026-08-20T01:14:22.563+00:00","Via Express Delivery United Parcel Service","2022-10-27",{"id":266,"raw":267,"subject":38,"body_html":271,"body_text":272,"firm_name":273,"letter_id":274,"created_at":131,"fei_number":19,"letter_url":275,"updated_at":276,"action_type":22,"case_status":23,"posted_date":277,"marcs_cms_no":278,"product_type":48,"closeout_date":19,"issuing_office":69,"recipient_name":279,"body_fetched_at":280,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":281,"medical_device_id":19,"response_letter_date":19},2705,[268,269,270,69,38,13,13,13],"\u003Ctime datetime=\"2022-05-03T13:20:00Z\">05\u002F03\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-04-07T04:00:00Z\">04\u002F07\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fglobal-imports-inc-626682-04072022\">Global Imports Inc.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ron McGill\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Global Imports Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4321 Kingwood Dr. #162\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Kingwood\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>77339-3700\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Southwest Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>April 7, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Re: CMS # 626682\u003C\u002Fp>\n\n\u003Cp>Dear Mr. McGill,\u003C\u002Fp>\n\n\u003Cp>On December 15, 2021 – January 5, 2022, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Global Imports Inc. located at 4321 Kingwood Dr. #162, Kingwood, TX 77339-3700. We also conducted an inspection on June 16, 2021 – July 21, 2021. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\n\n\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\">https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We have not received your response to the Form FDA 483a issued on January 26, 2022.\u003C\u002Fp>\n\n\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\n\n\u003Cp>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the food products you import, including:\u003Cbr>\n\u003Cbr>\n• Chopped Spinach imported from foreign supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>\n• Cut Cauliflower imported from foreign suppliers \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>\n• Cut Corn imported from foreign supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>\n• Diced Yellow Peaches imported from foreign supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at \u003Ca href=\"http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\">http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html\u003C\u002Fa>. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\n\n\u003Cp>Additionally, we note that you may meet the definition of a “very small importer” under 21 CFR 1.500. If you meet the definition, you are still required to follow FSVP requirements. If you are a very small importer and you choose to comply with the modified requirements in 21 CFR 1.512, you must document that you meet the definition of very small importer as required per 21 CFR 1.512(b)(1)(i). If this section applies and you choose to comply with the requirements in paragraph (b) of this section, you are required to comply with the requirements in sections 1.502, 1.503, and 1.509. However, you are not required to comply with the requirements in sections 1.504 through 1.508 or 1.510. In addition, for each food you import, you must obtain written assurance, before importing the food and at least every 2 years thereafter, that your foreign supplier is producing the food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 418 or 419 of the FD&amp;C Act, if either is applicable, and the implementing regulations, and is producing the food in compliance with sections 402 and 403(w) of the FD&amp;C Act (21 CFR 1.512(b)(3)(i)).\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Food and Drug Administration, Attention: Kendra J. Vieira, Compliance Officer, 2320 Paseo de las Americas, Suite 200, San Diego, CA 92154. If you have any questions regarding this letter, you may contact Kendra J. Vieira via email at\u003Cbr>\nKendra.Vieira@fda.hhs.gov. Please reference CMS # 626682 on any documents or records you provide to us and\u002For within the subject line of any email correspondence you send to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Todd Cato\u003Cbr>\nDivision Director\u003Cbr>\nDivision of Southwest Imports\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nRon McGill\n\nRecipient Title\n\nOwner\n\nGlobal Imports Inc.\n\n4321 Kingwood Dr. #162\n\nKingwood, TX 77339-3700\n\nUnited States\n\nIssuing Office:\n\nDivision of Southwest Imports\n\nUnited States\n\nApril 7, 2022\n\nWARNING LETTER\n\nRe: CMS # 626682\n\nDear Mr. McGill,\n\nOn December 15, 2021 – January 5, 2022, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Global Imports Inc. located at 4321 Kingwood Dr. #162, Kingwood, TX 77339-3700. We also conducted an inspection on June 16, 2021 – July 21, 2021. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\n\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\n\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\n\nAt the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations. We have not received your response to the Form FDA 483a issued on January 26, 2022.\n\nYour significant violations of the FSVP regulation are as follows:\n\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the food products you import, including:\n\n• Chopped Spinach imported from foreign supplier (b)(4), located in (b)(4)\n\n• Cut Cauliflower imported from foreign suppliers (b)(4), and (b)(4), located in (b)(4)\n\n• Cut Corn imported from foreign supplier (b)(4), located in (b)(4)\n\n• Diced Yellow Peaches imported from foreign supplier (b)(4), located in (b)(4)\n\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\n\nAdditionally, we note that you may meet the definition of a “very small importer” under 21 CFR 1.500. If you meet the definition, you are still required to follow FSVP requirements. If you are a very small importer and you choose to comply with the modified requirements in 21 CFR 1.512, you must document that you meet the definition of very small importer as required per 21 CFR 1.512(b)(1)(i). If this section applies and you choose to comply with the requirements in paragraph (b) of this section, you are required to comply with the requirements in sections 1.502, 1.503, and 1.509. However, you are not required to comply with the requirements in sections 1.504 through 1.508 or 1.510. In addition, for each food you import, you must obtain written assurance, before importing the food and at least every 2 years thereafter, that your foreign supplier is producing the food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 418 or 419 of the FD&C Act, if either is applicable, and the implementing regulations, and is producing the food in compliance with sections 402 and 403(w) of the FD&C Act (21 CFR 1.512(b)(3)(i)).\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\n\nPlease send your reply to Food and Drug Administration, Attention: Kendra J. Vieira, Compliance Officer, 2320 Paseo de las Americas, Suite 200, San Diego, CA 92154. If you have any questions regarding this letter, you may contact Kendra J. Vieira via email at\n\nKendra.Vieira@fda.hhs.gov. Please reference CMS # 626682 on any documents or records you provide to us and\u002For within the subject line of any email correspondence you send to us.\n\nSincerely,\n\n\u002FS\u002F\n\nTodd Cato\n\nDivision Director\n\nDivision of Southwest Imports","Global Imports Inc.","global-imports-inc-626682-04072022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fglobal-imports-inc-626682-04072022","2026-10-26T08:08:46.427492+00:00","2022-05-03","626682","Ron McGill","2026-08-20T01:57:23.431+00:00","2022-04-07",{"id":283,"raw":284,"subject":288,"body_html":289,"body_text":290,"firm_name":291,"letter_id":292,"created_at":111,"fei_number":19,"letter_url":293,"updated_at":294,"action_type":22,"case_status":23,"posted_date":295,"marcs_cms_no":296,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":19,"body_fetched_at":297,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":298,"medical_device_id":19,"response_letter_date":19},3494,[285,286,287,11,288,13,13,13],"\u003Ctime datetime=\"2021-03-02T15:00:00Z\">03\u002F02\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-03-01T05:00:00Z\">03\u002F01\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fageless-global-llc-612865-03012021\">Ageless Global, LLC\u003C\u002Fa>","Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Ageless Global, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2722 S. West Temple\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Salt Lake City\u003C\u002Fspan>, \u003Cspan>UT\u003C\u002Fspan> \u003Cspan>84115\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:agelesslabs@gmail.com\"> agelesslabs@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>WARNING LETTER\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Date: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; March 1, 2021\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>CC: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>agelessgloballab.com: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; agelessgloballabcom@domainsbyproxy.com\u003C\u002Fspan> &nbsp;&nbsp;&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>cvk365.com: &nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cvk365.com@domainsbyproxy.com\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>covid19mdhub.com:&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; covid19mdhub.com@domainsbyproxy.com\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>lionsfuel.com:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lionsfuel.com@domainsbyproxy.com\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>mdimmunespray.com:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mdimmunespray.com@domainsbyproxy.com\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>mdmouthspray.com:&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mdmouthspray.com@domainsbyproxy.com\u003C\u002Fspan> \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>RE:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>This is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address www.agelessgloballab.com, www.cvk365.com (which redirects to www.agelessgloballab.com),&nbsp;\u003C\u002Fspan>\u003Cspan>www.covid19mdhub.com, \u003C\u002Fspan>\u003Cspan>www.lionsfuel.com, www.mdimmunespray.com, www.mdmouthspray.com on January 19, 2021 and January 18, 2021, respectively.&nbsp; In addition, we have reviewed your social media websites https:\u002F\u002Fwww.instagram.com\u002Fimmunoralcvk365\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>, \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>https:\u002F\u002Fwww.instagram.com\u002Fageless_global_\u002F\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>, \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>https:\u002F\u002Fwww.facebook.com\u002FAgeless-Global-101773438401247, https:\u002F\u002Ftwitter.com\u002FAgeless_Global\u002F, and https:\u002F\u002Fwww.linkedin.com\u002Fcompany\u002Fageless-global\u002F where consumers are directed to your websites to purchase your products. The FDA has observed that your websites offer the products “Immunoral,” “Immune Plus,” “MD Immune Support Spray,” and “MD CVK-365 Mouth Spray” for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-19\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[1]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&amp;C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&amp;C Act, 21 U.S.C. § 331(a) and (d).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[2]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[3]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan> \u003Cspan>Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Some examples of the claims on your websites\u003C\u002Fspan> \u003Cspan>that establish the intended use of your products and misleadingly represent them as safe and\u002For effective for the treatment or prevention of COVID-19 include:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Immunoral is a therapeutic combination of CBD, nano-silver, specialized mineral oxide NSF-60 water, and Vitamin C that show promise to naturally defend against the current SARS-CoV-2 pathogen, the cause of COVID-19 in the body.”&nbsp; [From your webpage https:\u002F\u002Fwww.agelessgloballab.com\u002Fimmunoral\u003Cspan>].\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Immunoral Can Help You Protect Your Body Against COVID-19 By Supporting Your Natural Immune System . . . Immunoral Gives You Peace Of Mind, Protection, and Reassurance that You are Doing What is Possible to Defend Against COVID-19 . . . Immunoral Can Keep Your Body Stronger and Healthier to Defend against COVID-19 . . . Immunoral Effortlessly Helps Support Your Bodies [\u003Ci>sic\u003C\u002Fi>] Ability To Fight Off, Viruses Like COVID-19” [From your webpage https:\u002F\u002Fwww.agelessgloballab.com\u002Fimmunoral].\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“The Company’s portfolio of technology and products currently include two patent-pending, clinically tested COVID-19 defense products.” Referring to your MD CVK-365 Mouth Spray and\u003C\u002Fspan> \u003Cspan>Immunoral CVK-365 products. [From your website, www.agelessgloballab.com].\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>\u003Cspan>&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\"\u003C\u002Fspan>\u003Cspan>\u003Cspan>Immunoral CVK-365 . . . Immune-based Therapy for COVID-19 Defense . . .&nbsp;Immunoral Mouth Spray, an immune-based adjunct therapy combination of CBD, nano-silver and NSF 60 mineral oxide water (CVK-365) and Vitamin C that shows promise to naturally defend against the current SARS-CoV-2, the virus that causes COVID-19 in the body. This therapy is grounded in the science pertaining to the immune system with proven ingredients that work synergistically. An initial test group that has been taking Immunoral since March 2020 resulted in great success where not one participant has contracted COVID-19.” [From your website, www.agelessgloballab.com].\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“I Have Had Great Success Helping People Bounce Back Fast From COVID-19 With Two Specific Products That Have Been Tested On The COVID-19 Pathogen . . . The ability to naturally start attacking the COVID-19 as soon as you find out you have it.” Referring to your\u003C\u002Fspan> \u003Cspan>Immunoral CVK-365 product. [From your website, www.covid19mdhub.com].\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Tested and affordable, Immune Plus Mouth Spray supports natural immune defense to inactivate, attack and shield against foreign pathogens like COVID-19, to safeguard your health.” [From your website, www.lionsfuel.com].\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Take three minutes and learn Four Simple Things that Could Help Protect You from Viruses (Corona, Sars, Bird and others) . . . DON’T LIVE IN FEAR OF THE CORONA VIRUS . . . Weak immune systems make an easy target for viruses.&nbsp; Take action to start strengthening your immune system today.” Referring to your MD IMMUNE SUPPORT SPRAY product. [From your website, www.mdimmunespray.com].\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“MD CVK-365 Mouth Spray contains clinically proven CVK-365 water and other natural ingredients to help you naturally defend against pathogens including COVID-19 . . . Tested and affordable, MD CVK-365 Mouth Spray supports natural immune defense to inactivate, attack and shield against foreign pathogens like COVID-19, to safeguard your health . . . MD CVK-365 Mouth Spray Dual Action defense has been clinically tested by an Independent Research Lab (Clinical USA) on hard surfaces and is shown to inactivate the SARS-CoV-2 virus at over 98% within 2-minutes with no regrowth in 48-hours.”&nbsp; [From your website, www.mdmouthspray.com].\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“'With the vaccine being in question for kids 17 and younger, MD CVK-365 Mouth Spray is a viable option of added defense,’ said Ageless Global Medical Director, Dr. Steven E. Warren.” The post includes an image with your website address “AGELESSGLOBALLAB.COM” [From December 28, 2020 posts on your social media websites https:\u002F\u002Fwww.instagram.com\u002Fageless_global_\u002F and https:\u002F\u002Fwww.facebook.com\u002FAgeless-Global-101773438401247].\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Still looking for a last-minute Christmas gift?&nbsp; Give your loved ones the gift of protection against SARS-CoV-2, bacteria, and other viruses for the holidays with Immunoral.” The post includes an image with your website address “AGELESSGLOBALLAB.COM.” [From December 18, 2020 posts on your social media websites https:\u002F\u002Fwww.instagram.com\u002Fageless_global_\u002F and https:\u002F\u002Fwww.facebook.com\u002FAgeless-Global-101773438401247].\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“An initial test group has been taking Immunoral since Mar. 2020 with great success not contracting COVID-19.&nbsp; It is a combination of CBD, nano-silver, NSF-60 water, and Vitamin C, showing promise to naturally defend against the pathogen.” The post includes an image with your website address “AGELESSGLOBALLAB.COM.” [From a December 14, 2020 post on your social media website https:\u002F\u002Fwww.instagram.com\u002Fageless_global_\u002F\u003C\u002Fspan>\u003Cspan>].\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Help us create a solution to the pandemic.&nbsp; Available in raspberry lime flavors, Immunoral CVK-365 is an immune-based therapy for COVID-19 defense. Get 50% when you sign up to be a participant in our IRB research study.” The post includes your website address cvk365.com. [From December 9, 2020 posts on your social media websites https:\u002F\u002Fwww.instagram.com\u002Fageless_global_\u002F&nbsp;and https:\u002F\u002Fwww.facebook.com\u002FAgeless-Global-101773438401247].\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“How to use Immunoral?&nbsp; Spray it in your mouth five times in the morning and again five times at night.&nbsp; It will help you to naturally defend against the current SARS-CoV-2 pathogen, the cause of COVID-19 in the body. . . . [L]earn how you could join our immune defense study today.”&nbsp; [From November 2, 2020 posts on your social media websites https:\u002F\u002Fwww.instagram.com\u002Fageless_global_\u002F and https:\u002F\u002Fwww.facebook.com\u002FAgeless-Global-101773438401247].\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Ageless Global, LLC . . . a leading developer and supplier of physician-backed, clinically-tested wellness products to better equip our nation with the defense needed to combat COVID-19, announced today the launch of . . . Immunoral Oral Spray. . . an immune-based adjunct therapy combination of CBD, nano-silver, NSF 60 mineral oxide water (CVK-365) and Vitamin C that shows promise to naturally defend against SARS-CoV-2, the virus that causes COVID-19 in the body.”&nbsp; [From a press release titled, “Ageless Global Launches Clinically-Tested COVID-19 Defense Therapies and Products in Response to Pandemic” dated October 27, 2020, and accessible at https:\u002F\u002Fwww.accesswire.com\u002F612357\u002FAgeless-Global-Launches-Clinically-Tested-COVID-19-Defense-Therapies-and-Products-in-Response-to-Pandemic, linked from your website at www.agelessgloballab.com\u002Frecent-news].\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Immunoral: a new immune-based therapy against the COVID-19 pathogen” accompanied by an image of Immunoral and the text “WWW.CVK365.COM.” [From a December 30, 2020 post on your social media website https:\u002F\u002Fwww.instagram.com\u002Fimmunoralcvk365\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Immunoral CVK-365 . . . helps you naturally defend against the current SARS-CoV-2 pathogen . . . CVK365.COM” [From a December 22, 2020 post on your social media website https:\u002F\u002Fwww.instagram.com\u002Fimmunoralcvk365].\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Aiming to boost your #fitness during quarantine? Lion’s Fuel Immune Plus is a new mouth spray that supports natural #immune defense to shield against pathogens, like #COVID19” [From a January 19, 2021 tweet from your social media website https:\u002F\u002Ftwitter.com\u002FAgeless_Global\u002Fstatus\u002F1351629238961463298]. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>In addition, your Immunoral product is also misbranded under section 502 of the FD&amp;C Act, 21 U.S.C. § 352, because your firm’s website, product label and\u002For social media pages falsely suggest that the\u003Cbr>\n“Department of Health and Human Services (HHS) approved as an IRB study” using Immunoral. However, we note that the HHS does not approve studies and that the registration for the IRB that you list “IORG001078,” expired on April 14, 2014. For example, you state:\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“What precautions are you taking to protect yourself against COVID-19? We have developed a patent-pending, adjunct therapy, Immunoral oral spray that the Department of Health and Human Services approved as an IRB study. Learn more about the study: www.cvk365.com” \u003C\u002Fspan>\u003Cspan>[From a November 16, 2020 post on your social media website https:\u002F\u002Fwww.instagram.com\u002Fageless_global_\u002F].\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Join the Immunoral mouth spray COVID-19 Immune Defense Study! Department of Health and Human Services has approved the Immunoral IRB #(IORG001078) For more information about the Immunoral IRB click the link in the bio!” [From an October 7, 2020 post on your social media website https:\u002F\u002Fwww.instagram.com\u002Fimmunoralcvk365\u002F].\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Join our IRB study for Immunoral. This research will focus on a specialty adjunct therapeutic, which is proven effective in boosting the immune system, increasing the potential to naturally defend itself against the effects of the virus. https:\u002F\u002Fcvk365.com\u002F\u003C\u002Fspan> \u003Cspan>. . . #COVID19” [From your LinkedIn website https:\u002F\u002Fwww.linkedin.com\u002Fcompany\u002Fageless-global\u002F\u003Cspan>].\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>The label of your Immunoral product states “Available Only Through IRB Registration at www.CVK365.com.” \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>You should take immediate action to address the violations cited in this letter.&nbsp; This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations.&nbsp; It is your responsibility to ensure that the products you sell are in compliance with the FD&amp;C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that \u003C\u002Fspan>\u003Cspan>you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&amp;C Act\u003C\u002Fspan>\u003Cspan>. &nbsp;\u003Cb>Within 48 hours, please send an email to \u003C\u002Fb>\u003C\u002Fspan>\u003Cb>\u003Cspan>COVID-19-Task-Force-CDER@fda.hhs.gov\u003C\u002Fspan>\u003C\u002Fb>\u003Cb> \u003C\u002Fb>\u003Cspan>describing the specific steps you have taken to address these violations. &nbsp;Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation.&nbsp; \u003C\u002Fspan>\u003Cspan>Failure to adequately any violations may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19.&nbsp;Your firm will be added to a published list on \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>FDA’s\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan> website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&amp;C Act.&nbsp;This list can be found at \u003C\u002Fspan>http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\u003C\u002Fspan>\u003Cspan>\u003Cspan>. \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>Once you have taken actions\u003C\u002Fspan>\u003Cspan> to address the sale of your unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19,\u003C\u002Fspan>\u003Cspan> and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Please direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>In addition, it is unlawful under the FTC Act, 15 U.S.C. 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made.&nbsp; For COVID-19, no such study is currently known to exist for the product identified above.&nbsp; Thus, any coronavirus-related prevention or treatment claims regarding such product are not supported by competent and reliable scientific evidence.&nbsp; You must immediately cease making all such claims.&nbsp; Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. &nbsp;In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $43,792 per violation.&nbsp; Within 48 hours, please send an email to Richard Cleland, Assistant Director of the FTC’s Division of Advertising Practices, via electronic mail at rcleland@ftc.gov describing the specific actions you have taken to address the FTC’s concerns. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at \u003Cspan>202-326-3088\u003C\u002Fspan>.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Sincerely,&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u002FS\u002F\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Donald D. Ashley&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Director&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Office of Compliance&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Center for Drug Evaluation and Research&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Food and Drug Administration\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Sincerely,\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u002FS\u002F\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Serena Viswanathan\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Associate Director\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Division of Advertising Practices\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Federal Trade Commission\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cdiv>&nbsp;\n\u003Chr>\n\u003Cdiv>\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[1]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan> As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\n\u003Cdiv>\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[2]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>&nbsp;Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed) \u003Ci>available at\u003C\u002Fi> https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx. \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\n\u003Cdiv>\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[3]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), \u003Ci>available at\u003C\u002Fi> https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nAgeless Global, LLC\n\n2722 S. West Temple\n\nSalt Lake City, UT 84115\n\nUnited States\n\nagelesslabs@gmail.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nDate: March 1, 2021\n\nCC:\n\nagelessgloballab.com: agelessgloballabcom@domainsbyproxy.com\n\ncvk365.com: cvk365.com@domainsbyproxy.com\n\ncovid19mdhub.com: covid19mdhub.com@domainsbyproxy.com\n\nlionsfuel.com: lionsfuel.com@domainsbyproxy.com\n\nmdimmunespray.com: mdimmunespray.com@domainsbyproxy.com\n\nmdmouthspray.com: mdmouthspray.com@domainsbyproxy.com\n\nRE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) reviewed your website at the Internet address www.agelessgloballab.com, www.cvk365.com (which redirects to www.agelessgloballab.com), www.covid19mdhub.com, www.lionsfuel.com, www.mdimmunespray.com, www.mdmouthspray.com on January 19, 2021 and January 18, 2021, respectively. In addition, we have reviewed your social media websites https:\u002F\u002Fwww.instagram.com\u002Fimmunoralcvk365, https:\u002F\u002Fwww.instagram.com\u002Fageless_global_\u002F, https:\u002F\u002Fwww.facebook.com\u002FAgeless-Global-101773438401247, https:\u002F\u002Ftwitter.com\u002FAgeless_Global\u002F, and https:\u002F\u002Fwww.linkedin.com\u002Fcompany\u002Fageless-global\u002F where consumers are directed to your websites to purchase your products. The FDA has observed that your websites offer the products “Immunoral,” “Immune Plus,” “MD Immune Support Spray,” and “MD CVK-365 Mouth Spray” for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-19[1] in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d).\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.[2] In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.[3] Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nSome examples of the claims on your websites that establish the intended use of your products and misleadingly represent them as safe and\u002For effective for the treatment or prevention of COVID-19 include:\n\n“Immunoral is a therapeutic combination of CBD, nano-silver, specialized mineral oxide NSF-60 water, and Vitamin C that show promise to naturally defend against the current SARS-CoV-2 pathogen, the cause of COVID-19 in the body.” [From your webpage https:\u002F\u002Fwww.agelessgloballab.com\u002Fimmunoral].\n\n“Immunoral Can Help You Protect Your Body Against COVID-19 By Supporting Your Natural Immune System . . . Immunoral Gives You Peace Of Mind, Protection, and Reassurance that You are Doing What is Possible to Defend Against COVID-19 . . . Immunoral Can Keep Your Body Stronger and Healthier to Defend against COVID-19 . . . Immunoral Effortlessly Helps Support Your Bodies [sic] Ability To Fight Off, Viruses Like COVID-19” [From your webpage https:\u002F\u002Fwww.agelessgloballab.com\u002Fimmunoral].\n\n“The Company’s portfolio of technology and products currently include two patent-pending, clinically tested COVID-19 defense products.” Referring to your MD CVK-365 Mouth Spray and Immunoral CVK-365 products. [From your website, www.agelessgloballab.com].\n\n\"Immunoral CVK-365 . . . Immune-based Therapy for COVID-19 Defense . . . Immunoral Mouth Spray, an immune-based adjunct therapy combination of CBD, nano-silver and NSF 60 mineral oxide water (CVK-365) and Vitamin C that shows promise to naturally defend against the current SARS-CoV-2, the virus that causes COVID-19 in the body. This therapy is grounded in the science pertaining to the immune system with proven ingredients that work synergistically. An initial test group that has been taking Immunoral since March 2020 resulted in great success where not one participant has contracted COVID-19.” [From your website, www.agelessgloballab.com].\n\n“I Have Had Great Success Helping People Bounce Back Fast From COVID-19 With Two Specific Products That Have Been Tested On The COVID-19 Pathogen . . . The ability to naturally start attacking the COVID-19 as soon as you find out you have it.” Referring to your Immunoral CVK-365 product. [From your website, www.covid19mdhub.com].\n\n“Tested and affordable, Immune Plus Mouth Spray supports natural immune defense to inactivate, attack and shield against foreign pathogens like COVID-19, to safeguard your health.” [From your website, www.lionsfuel.com].\n\n“Take three minutes and learn Four Simple Things that Could Help Protect You from Viruses (Corona, Sars, Bird and others) . . . DON’T LIVE IN FEAR OF THE CORONA VIRUS . . . Weak immune systems make an easy target for viruses. Take action to start strengthening your immune system today.” Referring to your MD IMMUNE SUPPORT SPRAY product. [From your website, www.mdimmunespray.com].\n\n“MD CVK-365 Mouth Spray contains clinically proven CVK-365 water and other natural ingredients to help you naturally defend against pathogens including COVID-19 . . . Tested and affordable, MD CVK-365 Mouth Spray supports natural immune defense to inactivate, attack and shield against foreign pathogens like COVID-19, to safeguard your health . . . MD CVK-365 Mouth Spray Dual Action defense has been clinically tested by an Independent Research Lab (Clinical USA) on hard surfaces and is shown to inactivate the SARS-CoV-2 virus at over 98% within 2-minutes with no regrowth in 48-hours.” [From your website, www.mdmouthspray.com].\n\n“'With the vaccine being in question for kids 17 and younger, MD CVK-365 Mouth Spray is a viable option of added defense,’ said Ageless Global Medical Director, Dr. Steven E. Warren.” The post includes an image with your website address “AGELESSGLOBALLAB.COM” [From December 28, 2020 posts on your social media websites https:\u002F\u002Fwww.instagram.com\u002Fageless_global_\u002F and https:\u002F\u002Fwww.facebook.com\u002FAgeless-Global-101773438401247].\n\n“Still looking for a last-minute Christmas gift? Give your loved ones the gift of protection against SARS-CoV-2, bacteria, and other viruses for the holidays with Immunoral.” The post includes an image with your website address “AGELESSGLOBALLAB.COM.” [From December 18, 2020 posts on your social media websites https:\u002F\u002Fwww.instagram.com\u002Fageless_global_\u002F and https:\u002F\u002Fwww.facebook.com\u002FAgeless-Global-101773438401247].\n\n“An initial test group has been taking Immunoral since Mar. 2020 with great success not contracting COVID-19. It is a combination of CBD, nano-silver, NSF-60 water, and Vitamin C, showing promise to naturally defend against the pathogen.” The post includes an image with your website address “AGELESSGLOBALLAB.COM.” [From a December 14, 2020 post on your social media website https:\u002F\u002Fwww.instagram.com\u002Fageless_global_\u002F].\n\n“Help us create a solution to the pandemic. Available in raspberry lime flavors, Immunoral CVK-365 is an immune-based therapy for COVID-19 defense. Get 50% when you sign up to be a participant in our IRB research study.” The post includes your website address cvk365.com. [From December 9, 2020 posts on your social media websites https:\u002F\u002Fwww.instagram.com\u002Fageless_global_\u002F and https:\u002F\u002Fwww.facebook.com\u002FAgeless-Global-101773438401247].\n\n“How to use Immunoral? Spray it in your mouth five times in the morning and again five times at night. It will help you to naturally defend against the current SARS-CoV-2 pathogen, the cause of COVID-19 in the body. . . . [L]earn how you could join our immune defense study today.” [From November 2, 2020 posts on your social media websites https:\u002F\u002Fwww.instagram.com\u002Fageless_global_\u002F and https:\u002F\u002Fwww.facebook.com\u002FAgeless-Global-101773438401247].\n\n“Ageless Global, LLC . . . a leading developer and supplier of physician-backed, clinically-tested wellness products to better equip our nation with the defense needed to combat COVID-19, announced today the launch of . . . Immunoral Oral Spray. . . an immune-based adjunct therapy combination of CBD, nano-silver, NSF 60 mineral oxide water (CVK-365) and Vitamin C that shows promise to naturally defend against SARS-CoV-2, the virus that causes COVID-19 in the body.” [From a press release titled, “Ageless Global Launches Clinically-Tested COVID-19 Defense Therapies and Products in Response to Pandemic” dated October 27, 2020, and accessible at https:\u002F\u002Fwww.accesswire.com\u002F612357\u002FAgeless-Global-Launches-Clinically-Tested-COVID-19-Defense-Therapies-and-Products-in-Response-to-Pandemic, linked from your website at www.agelessgloballab.com\u002Frecent-news].\n\n“Immunoral: a new immune-based therapy against the COVID-19 pathogen” accompanied by an image of Immunoral and the text “WWW.CVK365.COM.” [From a December 30, 2020 post on your social media website https:\u002F\u002Fwww.instagram.com\u002Fimmunoralcvk365\n\n“Immunoral CVK-365 . . . helps you naturally defend against the current SARS-CoV-2 pathogen . . . CVK365.COM” [From a December 22, 2020 post on your social media website https:\u002F\u002Fwww.instagram.com\u002Fimmunoralcvk365].\n\n“Aiming to boost your #fitness during quarantine? Lion’s Fuel Immune Plus is a new mouth spray that supports natural #immune defense to shield against pathogens, like #COVID19” [From a January 19, 2021 tweet from your social media website https:\u002F\u002Ftwitter.com\u002FAgeless_Global\u002Fstatus\u002F1351629238961463298].\n\nIn addition, your Immunoral product is also misbranded under section 502 of the FD&C Act, 21 U.S.C. § 352, because your firm’s website, product label and\u002For social media pages falsely suggest that the\n\n“Department of Health and Human Services (HHS) approved as an IRB study” using Immunoral. However, we note that the HHS does not approve studies and that the registration for the IRB that you list “IORG001078,” expired on April 14, 2014. For example, you state:\n\n“What precautions are you taking to protect yourself against COVID-19? We have developed a patent-pending, adjunct therapy, Immunoral oral spray that the Department of Health and Human Services approved as an IRB study. Learn more about the study: www.cvk365.com” [From a November 16, 2020 post on your social media website https:\u002F\u002Fwww.instagram.com\u002Fageless_global_\u002F].\n\n“Join the Immunoral mouth spray COVID-19 Immune Defense Study! Department of Health and Human Services has approved the Immunoral IRB #(IORG001078) For more information about the Immunoral IRB click the link in the bio!” [From an October 7, 2020 post on your social media website https:\u002F\u002Fwww.instagram.com\u002Fimmunoralcvk365\u002F].\n\n“Join our IRB study for Immunoral. This research will focus on a specialty adjunct therapeutic, which is proven effective in boosting the immune system, increasing the potential to naturally defend itself against the effects of the virus. https:\u002F\u002Fcvk365.com\u002F . . . #COVID19” [From your LinkedIn website https:\u002F\u002Fwww.linkedin.com\u002Fcompany\u002Fageless-global\u002F].\n\nThe label of your Immunoral product states “Available Only Through IRB Registration at www.CVK365.com.”\n\nYou should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&C Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately any violations may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&C Act. This list can be found at http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products. Once you have taken actions to address the sale of your unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nIf you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov.\n\nIn addition, it is unlawful under the FTC Act, 15 U.S.C. 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the product identified above. Thus, any coronavirus-related prevention or treatment claims regarding such product are not supported by competent and reliable scientific evidence. You must immediately cease making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction and an order may require that you pay back money to consumers. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $43,792 per violation. Within 48 hours, please send an email to Richard Cleland, Assistant Director of the FTC’s Division of Advertising Practices, via electronic mail at rcleland@ftc.gov describing the specific actions you have taken to address the FTC’s concerns. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088.\n\nSincerely,\n\n\u002FS\u002F\n\nDonald D. Ashley\n\nDirector\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\nSincerely,\n\n\u002FS\u002F\n\nSerena Viswanathan\n\nAssociate Director\n\nDivision of Advertising Practices\n\nFederal Trade Commission\n\n[1] As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n[2] Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed) available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n[3] Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.","Ageless Global, LLC","ageless-global-llc-612865-03012021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fageless-global-llc-612865-03012021","2026-10-26T08:07:51.078901+00:00","2021-03-02","612865","2026-08-20T03:19:41.46+00:00","2021-03-01",15,{"510k":301,"classification":302,"enforcement":303,"event":304,"event_backfill":305,"pma":306,"warning_letter":307},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-20T04:00:32.497+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]